Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Genetically modified micro-organism, cell, or virus (e.g., transformed, fused, hybrid, etc.)

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424930100 - WHOLE LIVE MICRO-ORGANISM, CELL, OR VIRUS CONTAINING

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
424930210 Eukaryotic cell 474
Entries
DocumentTitleDate
20090324547Probiotic Oral Health Promoting Product - The present invention discloses an oral composition comprising a combination of probiotic bacteria selected from the group comprising 12-31-2009
20090214477Human Marker Genes and Agents for Diagnosis, Treatment and Prophylaxis of Cardiovascular Disorders and Artherosclerosis - The invention relates to novel targets in the screening for compounds useful in the treatment and/or prophylaxis of a disease selected from the group comprising cardiovascular diseases, disorders of lipid metabolism or atherosclerosis. The invention relates to novel compounds for use as a medicament for diseases or conditions involving a disease selected from the group comprising cardiovascular diseases, disorders of lipid metabolism or atherosclerosis. The invention especially relates to antagonists and expression-inhibitory compounds that target G-protein coupled receptors (GPCRs), kinases and proteases, and to methods for identifying such compounds. The invention further relates to methods for identifying these antagonists and expression-inhibitory compounds, and methods for diagnosing a disease selected from the group comprising cardiovascular diseases, disorders of lipid metabolism or atherosclerosis or a susceptibility to such a condition.08-27-2009
20120201784LONG LASTING DRUG FORMULATIONS - The present invention is directed to long-lasting erythropoietin therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes erythropoietin.08-09-2012
20090123428PATHOTROPIC TARGETED GENE DELIVERY SYSTEM FOR CANCER AND OTHER DISORDERS - Systems for pathotropic (disease-seeking) targeted gene delivery are provided, including viral particles with extremely high titers. In particular, the viral particles are engineered to specifically deliver therapeutic or diagnostic agents to a disease site, such as cancer metastic sites. Personalized dosing regimens are also provided to treat diseases such as cancer efficaciously with reduced adverse side effects.05-14-2009
20080260693METHODS FOR PRODUCING AND USING IN VIVO PSEUDOTYPED RETROVIRUSES USING ENVELOPE GLYCOPROTEINS FROM LYMPHOCYTIC CHORIOMENINGITIS VIRUS (LCMV) - The present invention provides novel pseudotyped retroviral vectors that can transduce human and other cells. Vectors are provided that are packaged efficiently in packaging cells and cell lines to generate high titer recombinant virus stocks expressing novel envelope glycoproteins. The present invention further relates to compositions for gene therapy.10-23-2008
20090074722Products and methods for treating PTP lar diseases - The present invention relates to methods and products useful for the treatment of various epithelial cell migration diseases and disorders, and to methods useful for the identification of various products useful for the treatment of these diseases and disorders. In particular, methods for treating using PTP LAR are described, as are methods for identifying compounds to modulate PTP LAR activity.03-19-2009
20100080774LACTOCOCCUS PROMOTERS AND USES THEREOF - The invention is in the field of molecular biology, and relates to recombinant engineering and protein expression. More in particular, the invention relates to nucleic acids for recombinant expression of proteins comprising sequences derived from 04-01-2010
20110195050USE OF A COMBINATION OF MYXOMA VIRUS AND RAPAMYCIN FOR THERAPEUTIC TREATMENT - The present invention relates to therapeutic use of a combination of Myxoma virus, including in combination with rapamycin. Treatment with rapamycin enhances the ability of Myxoma virus to selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon. The combination of rapamycin and Myxoma virus can be used to treat diseases characterized by the presence of such cells, including cancer. The invention also relates to therapeutic use of Myxoma virus that does not express functional M135R.08-11-2011
20090191156GM-CSF COSMECEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF - It has been discovered that granulocyte macrophage colony stimulating factor (“GM-CSF”) promotes migration of activated (but not differentiating) keratinocytes to wound sites. It was also discovered that GM-CSF increases the quantity and improves the quality of collagen. This growth factor specifically increases migration of keratinocytes of the “wound” phenotype but does not have significant effects upon differentiated keratinocytes. Examples demonstrate reversal of skin impairment in multiple animal models of diabetic skin imparment when provided in an effective amount over an effective time period. The examples also demonstrate the efficacy of the formulations in cosmetic applications. A preferred formulation is a sustained release formulation that delivers sufficient growth factor to the skin and the underlying tissue thereof to increase the rate of keratinocyte migration, as well as collagen deposition and fibroblast proliferation, in the skin to promote rejuvenation of skin injuries resistant to repair due to underlying disease, such as diabetes, or aging.07-30-2009
20090191155COMPOSITIONS AND METHODS FOR AMELIORATING MYOSIN VIIA DEFECTS - The invention provides compositions and methods for ameliorating defects in myosin VIIa (MYO7A) expression and/or function, including providing vectors for myosin VIIa expression and formulations comprising them, and methods of using them, for treating human retinitis pigmentosa (or retinal degeneration), and blindness and deafness such as that found in Usher syndrome. The invention provides in vivo gene therapy for ameliorating defects in myosin VIIa (MYO7A) expression and/or function, including compositions and methods for gene transfer of the human myosin VIIa (MYO7A) gene (the MYO7A gene.07-30-2009
20100158867PARAMYXOVIRUS VECTOR ENCODING ANGIOGENESIS GENE AND USE THEREOF - The present invention provides Paramyxovirus vectors encoding angiogenic genes and use of the same. The use of Paramyxovirus vectors enables effective transfer of angiogenic genes into individual tissues. FGF2 gene transferred into ischemic tissues in vivo induces expression of angiogenic genes without causing edema, and prevents necrosis due to ischemia. The vectors of the present invention are suitable for gene therapy targeted to ischemic tissues.06-24-2010
20100150871Genetically-modified strain of yeast with an increased production and output of s-adenosylmethionine (sam) - The invention relates to a genetically-modified strain of yeast, in which the gene coding for adenosine kinase has been inactivated by genetic modification for the production of S-adenosylmethionine (SAM).06-17-2010
20100008889ADENOVIRAL EXPRESSION VECTORS - The present invention provides a recombinant adenovirus vector characterized by the partial or total deletion of adenoviral E2B function and having an expression cassette containing a heterologous sequence encoding a protein of interest inserted into the E1 region. Such vectors are designed to reduce or eliminate the occurrence of replication competent adenovirus contamination. Additionally, the expression cassette of the vector may contain one or more regulatory elements capable of increasing the expression of the heterologous sequence and/or reducing the expression of viral proteins. Such a reduction in expression of viral proteins reduces the cytotoxicty and immunogenicity of the adenovirus vectors when administered in vivo. Transformed production host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention.01-14-2010
20130084264ANTI-TUMOR COMPOSITION - The present invention relates to pharmaceutical compositions comprising Avian Paramyxovirus (APMV) for use in the treatment of a tumor in a mammal.04-04-2013
20100074869Multifunctional Cytokines - The present invention relates to a novel fusion protein with the formula X-Y, or Y-X, wherein X represents a first immunoregulating polypeptide and Y represents a second immunoregulating polypeptide different from X. The present invention also relates to a nucleic acid molecule encoding such a fusion protein and a vector comprising such a nucleic acid molecule. The present invention also provides infectious viral particles and host cells comprising such a nucleic acid molecule or such a vector as well as a process for producing such infectious viral particles. The present invention also relates to a method for recombinantly producing such a fusion protein. Finally, the present invention also provides a pharmaceutical composition comprising such a fusion protein, a nucleic acid molecule, a vector, infectious viral particles and a host cell as well as the therapeutic use thereof.03-25-2010
20120244123THERAPEUTIC AGENTS - A purified anti-cancer peptide consisting of amino acids 266 to 287 of Genbank Accession No. O68604 (SEQ ID No. 4), and modified and homologous forms of the peptide are described. The modified or and homologous forms of the peptide include more than contiguous amino acids having at least 75% amino acid sequence identity with at least 8 contiguous amino acids of amino acids 266-287 of Genbank Accession No. O68604 (SEQ ID No.4) defining a motif selected from the group consisting of RRRVQQ (SEQ ID No. 5) and RGRAK (SEQ ID No.1). The peptide(s) can be produced by 09-27-2012
20130078219GENETICALLY MODIFIED PARAMYXOVIRUS FOR TREATMENT OF TUMOR DISEASES - The present invention relates to a genetically modified Paramyxovirus, a pharmaceutical composition comprising this paramyxovirus, the use of a genetically modified Paramyxovirus for the therapeutic and/or prophylactic treatment of a tumor disease, and a method for the production of a pharmaceutical composition for the therapeutic or prophylactic treatment of a tumor disease.03-28-2013
20120183502COMBINATION THERAPY FOR LYSOSOMAL STORAGE DISEASES - This invention provides various combinations of enzyme replacement therapy, gene therapy, and small molecule therapy for the treatment of lysosomal storage diseases.07-19-2012
20120183503LACTOBACILLUS AND STREPTOCOCCUS PROMOTERS AND USES THEREOF - The invention is in the field of molecular biology, and relates to recombinant engineering and protein expression. More in particular, the invention relates to nucleic acids for recombinant expression of proteins comprising sequences derived from 07-19-2012
20130084263Pharmaceutical kit and method for treating cancer - This invention is related to the field of cancer treatment, more specifically to gene therapy in combination with a suitable chemotherapeutic agent. The present invention is related to a new oncolytic virus, which is able to inhibit the growth of malignant tumors or is a treatment of hyperproliferative mammalian cells, or is a treatment of cancer. The oncolytic virus works in combination with a suitable chemotherapeutic agent. More specifically, the present invention provides a pharmaceutical kit comprising an oncolytic adenovirus and a chemotherapeutic agent, and a method for the treatment of cancer.04-04-2013
20130034523USE OF SDF-1 TO MITIGATE SCAR FORMATION - The subject matter provided herein relates to method for inhibiting or mitigating scar formation in a wound of the skin, by increasing the concentration of SDF-1 in, or proximate to, the wound. As described herein SDF-1 protein or an SDF-1 expression vector can be administered to a wound or the area proximate a wound by providing a therapeutically effective amount of SDF-1 protein or an SDF-1 expression vector.02-07-2013
20130039889RECOMBINANT MICROORGANISMS - The invention relates to a recombinant microorganism comprising a transgene encoding angiogenin and optionally follistatin, a food product, beverage product or animal feed produced from or comprising said microorganism and uses thereof.02-14-2013
20130039890TREATMENT OF TUMORS WITH GENETICALLY ENGINEERED HERPES VIRUS - Disclosed are methods for treating cancer by administering an effective amount of a modified Herpes simplex virus.02-14-2013
20130039888PRODUCTS AND METHODS FOR DELIVERY OF POLYNUCLEOTIDES BY ADENO-ASSOCIATED VIRUS FOR LYSOSOMAL STORAGE DISORDERS - The present invention relates to methods and materials useful for systemically delivering polynucleotides across the blood brain barrier using adeno-associated virus as a vector. For example, the present invention relates to methods and materials useful for systemically delivering α-N-acetylglucosamidinase polynucleotides to the central and peripheral nervous systems, as well as the somatic system. Use of these methods and materials is indicated, for example, for treatment of the lysosomal storage disorder mucopolysaccharidosis IIIB. As another example, the present invention relates to methods and materials useful for systemically delivering N-sulphoglucosamine sulfphohydrolase polynucleotides to the central and peripheral nervous systems, as well as the somatic system. Use of this second type of methods and materials is indicated, for example, for treatment of the lysosomal storage disorder mucopolysaccharidosis IIIA.02-14-2013
20100098665METHOD OF CANCER TREATMENT - A method and composition for treating cancer comprising administering to a patient an effective amount of attenuated 04-22-2010
20090068148PEPTIDES OF CAV2.2 THAT INHIBIT PAIN - The present invention relates to peptides of CaV2.2 and their use in the treatment of pain. The sequence of the peptides is derived from the C-terminus of CaV2.2. and is believed to inhibit the interaction of CaV2.2 with Mint1-PDZ1. The invention is related to use of this peptide to treat pain and to use of this peptide in binding reaction with int-PDZ to screen for small molecules that can inhibit pain.03-12-2009
20130209405RECOMBINANT BACTERIUM TO DECREASE TUMOR GROWTH - A recombinant bacterium capable of reducing tumor growth is provided, wherein said recombinant bacterium is capable of: a. increased expression of a nucleic acid encoding a chemoreceptor that directs chemotaxis towards tumors, b. accumulation in a quiescent tumor, c. hyper-invasion of a tumor, d. reduced fitness in normal tissue, e. enhanced stimulation of the host innate immune responses, f. delivering a tumor specific DNA vaccine vector to a tumor cell, and g. increased bacterium-induced host programmed cell death.08-15-2013
20100104535Methods of treating anemia using recombinant adeno-associated virus virions - The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue in the treatment of anemia is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of a delivered nucleotide sequence encoding erythropoietin, and for in vivo secretion thereof from transduced muscle cells such that systemic delivery is achieved.04-29-2010
20090155214NOVEL BACTERIA AND METHOD FOR CONTROLLING PLANT DISEASE USING THE SAME - An object of the present invention is to provide a means for imparting resistance against pathogenic fungal, pathogenic bacterial, or pathogenic viral disease to agriculturally useful plants. The present invention relates to a bacterium belonging to the genus 06-18-2009
20090155213LACTOBACILLUS ACIDOPHILUS NUCLEIC ACIDS AND USES THEREOF - NCFM nucleic acid molecules, polypeptides, fragments and variants thereof are provided in the current invention. In addition, fusion proteins, antigenic peptides, and antibodies are encompassed. The invention also provides recombinant expression vectors containing a nucleic acid molecule of the invention and cells comprising the expression vectors. Methods for producing the polypeptides of the invention and methods for their use are further provided.06-18-2009
20090155215ENGINEERED ENZYMATICALLY ACTIVE BACTERIOPHAGE AND METHODS FOR DISPERSING BIOFILMS - The present invention is directed to engineered enzymatically active bacteriophages that are both capable of killing the bacteria by lysis and dispersing the bacterial biofilm because they have been also engineered to express biofilm-degrading enzymes, particularly dispersin B (DspB), an enzyme that hydrolyzes β-1,6-N-acetyl-D-glucosamine, a crucial adhesion molecule needed for biofilm formation and integrity in 06-18-2009
20090280088Method of controlling hair shape - The present invention provides a method for determining or modulating hair morphology and properties of natural wavy and frizzy hair and a method for evaluating or selecting a hair morphology modulator. The present invention provides a method for modulating hair morphology, including controlling an expression of IGFBP-5 gene or IGFBP-5 protein in a human hair follicle.11-12-2009
20130045184BIOLOGIC FEMALE CONTRACEPTIVES - This invention provides, inter alia, commensal organisms engineered to express antibody fragments, which inhibit sperm motility or fertilization and compositions comprising the same. The present invention provides for the use of the engineered commensal organisms or compositions comprising the same as effective contraceptive means in females.02-21-2013
20120213737COMPOSITIONS AND METHODS FOR THERAPEUTIC MEMBRANE REPAIR - Disclosed herein are compositions comprising PTRF polypeptides, nucleic acids, and PTRF binding proteins useful for tissue regeneration and the treatment and prevention of disorders relating to cell membrane damage and repair.08-23-2012
20100330039Schizochytrium Fatty Acid Synthase (FAS) and Products and Methods Related Thereto - Disclosed are a fatty acid synthase (FAS) from 12-30-2010
20100330038METHODS FOR EXPRESSING PROTEINS IN AXONS - The invention relates to expressing proteins in the axons of mammalian polypeptide in neuronal axons, viruses that can be used deliver nucleic acids of the invention into neuronal axons, as well as methods for doing so. Thus, the invention provides pharmaceutical compositions comprising viruses of the invention, as well as their use in methods of treating injured axons or conditions associated with aberrant axon growth or function.12-30-2010
20100330037ADENOVIRAL SYSTEMS AND THE USES THEREOF - The invention is related to a nucleic acid comprising an adenoviral nucleic acid, which also comprises a nucleic acid sequence coding for YB-1.12-30-2010
20120164108VIRUS STRAINS - The present invention relates to non-laboratory virus strains, for example of herpes viruses such as HSV, with improved oncolytic and/or gene delivery capabilities as compared to laboratory virus strains.06-28-2012
20120164107CYCLIC DI-AMP INDUCTION OF TYPE I INTERFERON - Methods of modulating type-I interferon production in a cell are provided. Aspects of the methods include modulating cytosolic cyclic di-adenosine monophosphate (c-di-AMP) activity in the cell in a manner sufficient to modulate type-I interferon production in the cell. Additional aspects of the invention include c-di-AMP activity modulatory compositions, e.g., c-di-AMP, mutant 06-28-2012
20120164105CONSTRUCTION OF A QUADRUPLE ENTEROTOXIN-DEFICIENT MUTANT OF BACILLUS THURINGIENSIS - Some HBL and NHE enterotoxins are known to cause food-borne diseases in humans. Enterotoxin-deficient mutants of member strains of the 06-28-2012
20130028868CLINICAL APPLICATIONS OF A RECOMBINANT HUMAN ENDOSTATIN ADENOVIRUS (E10A) INJECTION - The present invention relates to the genetic engineering field of angiogenesis-targeted therapy. Particularly, a recombinant human endostatin adenovirus injection is used along with certain antitumor agents for treating specific tumors. The methods of the invention offer significant improvement of effective response rate, disease control rate, survival and quality of life. The injection and treatment has no significant adverse reactions and side effects.01-31-2013
20130089523ADENOVIRUS DERIVED HELPER VIRUS FOR ENHANCING RECOMBINANT PARVOVIRUS PRODUCTION - Described is an adenovirus derived helper virus which may comprise the adenoviral DNA sequences for E2a, S4 (orf6), the VA1 RNA gene, and the parvovirus VP capsid gene unit. Also described is a method of efficiently preparing a recombinant parvovirus (particle) which is based on the use of various adenoviral derived helper viruses/vectors.04-11-2013
20130089522HETEROLOGOUS HOSTS - This invention is related to bacterial engineering and the heterologous expression of useful compounds. In particular, the invention relates to a heterologous host that has been engineered for expression of a gene which is capable of polyketide or non-ribosomal peptide synthesis. Methods of treating cancer are also disclosed.04-11-2013
20130052164ISOLATED NUCLEOTIDE MOLECULE AND METHOD OF SENSING AND KILLING OF PATHOGENIC MICROORGANISM - The present invention relates to an isolated nucleic acid molecule comprising a first nucleotide sequence encoding a protein that detects the presence, amount or both of a pathogenic microorganism by forming a complex with a protein produced by said pathogenic microorganism; a second nucleotide sequence encoding an antimicrobial peptide, wherein the antimicrobial peptide is effective against the pathogenic microorganism detected by the protein encoded by the first nucleotide sequence, wherein the second nucleotide sequence is under control of a promoter that is induced by the complex of the protein encoded by the first nucleotide sequence and the protein produced by said pathogenic microorganism. A recombinant microorganism comprising the isolated nucleic acid molecule and a method of sensing and killing pathogenic microorganisms is also described.02-28-2013
20090022690BACTERIAL TRANSLOCATION INHIBITOR AND METHOD OF INHIBITING BACTERIAL TRANSLOCATION - A bacterial translocation inhibitor containing live 01-22-2009
20100135961LIVE BACTERIAL VACCINES RESISTANT TO CARBON DIOXIDE (CO2), ACIDIC PH AND/OR OSMOLARITY FOR VIRAL INFECTION PROPHYLAXIS OR TREATMENT - The present invention relates to gram-negative bacterial mutants resistant to one or more stress conditions, including, but not limited to, CO06-03-2010
20090304637RECOMBINANT MYCOBACTERIUM STRAIN EXPRESSING A MYCOBACTERIAL FAP PROTEIN UNDER THE CONTROL OF A PROMOTER ACTIVE UNDER HYPOXIA AND ITS APPLICATION FOR CANCER THERAPY - The invention relates to a recombinant vector comprising a mycobacterial FAP protein coding sequence under the transcriptional control of a promoter active under hypoxia conditions and its use for the prevention and the treatment of epithelial tumors.12-10-2009
20090304636Stem Cell Factor Therapy for Tissue Injury - The present invention relates to the use of stem cell factor (SCF) for the treatment of ischemic injured tissue such as in cardiovascular disease. The method involves administration of a nucleic acid encoding SCF, wherein the nucleic acid is delivered to the site of the injury and is incorporated into cells which then express the SCF.12-10-2009
20090041726TUMOR THERAPY WITH HIGH AFFINITY LAMININ RECEPTOR-TARGET VECTORS AND COMBINATIONS WITH CHEMOTHERAPEUTIC AGENTS - The present invention relates to methods and compositions for treating tumors using vectors that preferentially target tumor cells. In particular, the invention relates to alphavirus-based, preferably Sindbis virus-based, vectors and to non-alphavirus-based vectors, which have a preferential affinity for high affinity laminin receptors (HALR). These vectors are efficiently targeted to tumors and have the ability to cause tumor necrosis.02-12-2009
20090041725Replication-Deficient RNA Viruses as Vaccines - The present invention relates to a genome-replication-deficient and transcription-competent negative-strand RNA virus, which can be used for the expression of transgenes and in particular for the area of vaccine development.02-12-2009
20130071355Recombinant Herpes Virus and Pharmaceutical Composition Containing The Same - An object of the present invention is to provide a highly-safe recombinant herpes virus showing high antitumor activity regardless of the kind, grade of malignancy, or growth rate of tumor cells.03-21-2013
20090092583BRAIN-LOCALIZING CELLS AND USES THEREOF - It was discovered that cells expressing brain-localizing polypeptides on the cell surface can pass through the blood-brain barrier and therefore have the activity of translocating to the brain. By introducing desired substances into such brain-localizing cells, the substances can also be translocated to the brain. For example, by intravenously administering brain-localizing cells into which pharmaceutical agents having therapeutic effects on brain diseases have been introduced, such agents can be efficiently delivered into the brain and the brain diseases can be effectively treated.04-09-2009
20130058897HEXON ISOLATED FROM SIMIAN ADENOVIRUS SEROTYPE 19, HYPERVARIABLE REGION THEREOF AND CHIMERIC ADENOVIRUS USING THE SAME - Novel hexon isolated from simian adenovirus serotype 19 encoded in the polynucleotide defined as SEQ ID NO: 3, hepervariable region thereof, chimeric adenovirus comprising the same, and therapeutic use thereof provides a solution to the problem of safety and effective systemic treatment for developing gene therapeutic agents using adenovirus.03-07-2013
20080206200Selected endothelial progenitor cells and methods for use - The present invention is a method for preparing a substantially pure population of endothelial progenitor cells wherein said cells express Flk-1, CD34, α08-28-2008
20130164262Recombinant Viruses and their Use for Treatment of Atherosclerosis and Othe Forms of Coronary Artery Disease and Method, Reagent, and Kit for Evaluating Susceptibiity to Same - Recombinant viruses comprising a heterologous DNA sequence coding for a lipase involved in lipoprotein metabolism. The invention also concerns the preparation and use in therapy of said recombinant viruses, especially for the treatment or prevention of dyslipoproteinemia-related pathologies.06-27-2013
20090238795In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors - A method for treating a renal disease in a subject is disclosed. The method includes administering into a kidney of the subject with an effective amount of a gutless adenoviral vector containing a polynucleotide encoding a therapeutic agent. The gutless adenoviral vector contains the nucleotide sequence of SEQ ID NO:13 or SEQ ID NO:15 and expresses the therapeutic agent in a kidney tissue of the subject.09-24-2009
20090280090METHODS OF TREATING PIGS WITH BACILLUS STRAINS - Disclosed are methods of administering at least two 11-12-2009
20120114606Novel Pasteuria Strain and Uses Thereof - The subject invention provides a novel and advantageous strain of 05-10-2012
20090010889Treatment Using Herpes Simplex Virus - The use of Herpes Simplex Virus (HSV) in the treatment of tumour by extratumoural administration of said HSV, and the use of HSV in treatment of tumour by combination therapy with a pharmaceutical wherein the HSV and/or pharmaceutical is administered at an extratumoural location, is disclosed.01-08-2009
20090010888Use of cytochrome P450 reductase as insecticidal target - The invention provides a method of enhancing the effectiveness of pesticides, as well as pesticidal formulations. Furthermore, it also provides the means for the de novo rational design of pesticides. The present invention also relates to a method of screening agents for potential use in insecticides, particularly against mosquitoes.01-08-2009
20080305083GFAP-BASED GENE THERAPY FOR TREATMENT OF RETINAL DISEASES - Compositions and methods for reducing neovascularization. Purified nucleic acid constructs and vectors encoding an anti-angiogenic protein operably linked to a GFAP promoter. Vectors can include at least one hypoxia regulated element, enhancer element and silencer element. Gene therapy methods for reducing, delaying or preventing neovascularization based on the nucleic acid constructs and vectors.12-11-2008
20130183271Methods and Compositions Concerning Poxviruses and Cancer - The present invention concerns methods and compositions for the treatment of cancer and cancer cells using altered poxviruses, including a vaccinia virus that has been altered to generate a more effective therapeutic agent. Such poxviruses are engineered to be attenuated or weakened in their ability to affect normal cells. In some embodiments, methods and compositions involve poxviruses that possess mutations that result in poxviruses with diminished or eliminated capability to implement an antiviral response in a host. Poxviruses with these mutations in combination with other mutations can be employed for more effective treatment of cancer.07-18-2013
20090175828Coagulation Factor X Polypeptides With Modified Activation Properties - The present invention relates to modified cDNA sequences coding for factor X polypeptides, in particular human factor X and its derivatives which can bypass the need for either factor VIIIa/factor IXa or factor VIIa/tissue factor for activation. The invention relates further to recombinant expression vectors containing such modified cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having altered activation properties, and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.07-09-2009
20110091425Upregulation of opioid receptors for management - Disclosed are methods for treating pain in a subject. The method includes upregulating expression of opioid receptors in the subject's dorsal root ganglion or trigeminal neurons. Also disclosed are methods of treating neuropathic and/or chronic pain in a subject. The method includes upregulating expression of μ-opioid or δ-opioid receptors in the subject's dorsal root ganglion or trigeminal neurons.04-21-2011
20100291035 Respiratory syncytial virus with a genomic deficiency complemented in trans - The invention relates to pneumoviral virions comprising a viral genome that has a mutation in a gene coding for a protein that is essential for infectivity of the pneumovirus, whereby the mutation causes a virus produced from only the viral genome to lack infectivity, and whereby the virion comprises the protein in a form and in an amount that is required for infectivity of the virion. The invention also relates to methods for producing the pneumoviral virions and for using the virions in the treatment or prevention of pneumoviral infection and disease. A preferred pneumoviral virion is a virion of Respiratory Syncytial Virus in which preferably the gene for the G attachment protein is inactivated and complemented in trans.11-18-2010
20110280835COMMENSAL BACTERIA AS SIGNAL MEDIATORS WITHIN A MAMMALIAN HOST - Genetically engineered cells and microorganisms are provided for preventing or ameliorating diseases through genetically engineered quorum signaling. Therapeutic methods for using the cells and microorganism to prevent or ameliorate diseases are also provided. The genetically engineered cells or microorganisms can be engineered to express a signal and used to interrupt the signaling-dependent virulence of an invading pathogen. The cells or microorganisms can be used to provide signal-dependent expression of a desirable gene in order to interrupt, prevent, and/or ameliorate a disease of mammals, such as parasitic diseases, infectious diseases, autoimmune diseases and genetic disorders.11-17-2011
20110280836COMPOSITIONS FOR BACTERIAL MEDIATED GENE SILENCING AND METHODS OF USING THE SAME - The invention features compositions and methods for delivering small interfering (siRNAs), e.g., shRNAs, to host cells using non-pathogenic strains of 11-17-2011
20100322903ENGINEERED BACTERIOPHAGES AS ADJUVANTS FOR ANTIMICROBIAL AGENTS AND COMPOSITIONS AND METHODS OF USE THEREOF - The present invention relates to the treatment and prevention of bacteria and bacterial infections. In particular, the present invention relates to engineered bacteriophages used in combination with antimicrobial agents to potentiate the antimicrobial effect and bacterial killing by the antimicrobial agent. The present invention generally relates to methods and compositions comprising engineered bacteriophages and antimicrobial agents for the treatment of bacteria, and more particularly to bacteriophages comprising agents that inhibit antibiotic resistance genes and/or cell survival genes, and/or bacteriophages comprising repressors of SOS response genes or inhibitors of antimicrobial defense genes and/or expressing an agent which increases the sensitivity of bacteria to an antimicrobial agent in combination with at least one antimicrobial agent, and their use thereof.12-23-2010
20090324549PROTEINS AND/OR PEPTIDES FOR THE PREVENTION AND/OR TREATMENT OF NEURODEGENERATIVE DISEASES - Proteins and/or peptides originate from the gene which results from the retention of the intron 3 of the gene SMN identified in the gene bank with the access number AY876898 with use for the diagnosis and/or prevention and/or treatment of neurodegenerative diseases. 12-31-2009
20090196854METHODS AND COMPOSITIONS FOR USE OF CRL 5803 CELLS FOR EXPRESSION OF BIOTHERAPEUTICS AND ENCAPSULATED CELL-BASED DELIVERY - The use of CRL 5803 cells as a robust cell substrate for transgene expression of polypeptides is contemplated. Furthermore, use of CRL 5803 cells in cell-based delivery and methods of making and using the same in encapsulated devices are contemplated.08-06-2009
20120087894PRODUCER CELLS FOR REPLICATION COMPETENT RETROVIRAL VECTORS - The disclosure provide cell lines and methods for the production of vectors and viral particles useful in gene therapy.04-12-2012
20110286971TARGETED DRUG-CARRYING BACTERIOPHAGES - The present invention relates to the field of drug delivery. More specifically, the invention relates to the preparation and use of a bacteriophage conjugated through a labile/non labile linker or directly to at least 1,000 therapeutic drug molecules such that the drug molecules are conjugated to the outer surface of the bacteriophage. The bacteriophage optionally displays on its coat a ligand that endows it with specificity towards target cells. Thus, there is provided a targeted, high-capacity drug delivery system useful for the treatment of various pathological conditions.11-24-2011
20090202491Method for modulating, regulating and/or stabilizing angiogenesis - A method of modulating, regulating and/or stabilizing angiogenesis in a mammal in need thereof, in which the PDGF-D level or activity or both in the mammal are modulated or increased. In preferred embodiments, an active PDGF-D polypeptide, or a polynucleotide encoding an active PDGF-D is administered to the mammal, preferably at a location where angiogenesis modulation or stabilization is desired. The PDGF-D is advantageously co-administered with an angiogenic growth factor, such as a member of the VEGF family of growth factors, in particular VEGF-E. The claimed method inhibits leakage of blood vessels and is useful, inter alia, for treatment of edemas.08-13-2009
20090202490MUTANT ADENO-ASSOCIATED VIRUS VIRIONS AND METHODS OF USE THEREOF - The present invention provides mutant adeno-associated virus (AAV) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant AAV comprising one or more mutations in a capsid gene. The present invention further provides methods of generating the mutant AAV and mutant AAV libraries, and compositions comprising the mutant AAV. The present invention further provides recombinant AAV (rAAV) virions that comprise a mutant capsid protein. The present invention further provides nucleic acids comprising nucleotide sequences that encode mutant capsid proteins, and host cells comprising the nucleic acids. The present invention further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof.08-13-2009
20110038836Device and Method for Transfecting Cells for Therapeutic Use - This invention generally relates to devices and methods for transfection of living cells using electroporation, in particular high throughput microtluidic electroporation, and to therapeutic uses of the transfected cells.02-17-2011
20110293566DIFFOCIN AND METHODS OF USE THEREOF - This disclosure relates to the discovery and isolation of the entire cluster of genes encoding R-type high molecular weight bacteriocins that specifically kill 12-01-2011
20110293567USE OF BACTERIA FOR THE SENSING AND KILLING OF CANCER CELLS - The present invention relates to the field of cancer therapy. Specifically, a chemotaxis fusion-receptor that directs bacteria towards tumors is disclosed. Further encompassed by the present invention is a bacterial cell that comprises at least one chemotaxis fusion-receptor and, preferably, a killing module for the destruction of tumor cells.12-01-2011
20090220459NON-PATHOGENIC AND/OR ATTENUATED BACTERIA CAPABLE OF INDUCING APOPTOSIS IN MACROPHAGES, PROCESS OF MANUFACTURING AND USES THEREOF - The invention relates to an non-pathogenic and/or attenuated bacterium which is capable of inducing apoptosis in macrophages.09-03-2009
20110300107Compositions and Methods to Treat Cardiac Pacing Conditions - The method may include administering to a subject in need thereof an effective amount of an HCN polynucleotide. The HCN polynucleotide includes a nucleotide sequence encoding an HCN polypeptide having channel activity. The amino acid sequence of the HCN polypeptide and the amino acid sequence of a reference polypeptide have at least 80% identity, where the reference polypeptide begins with an amino acid selected from amino acids 92-214 and ends with an amino acid selected from amino acids 723-1188 of SEQ ID NO:8. An example of a reference polypeptide is amino acids 214-723 of SEQ ID NO:8. The HCN polynucleotide may be DNA or RNA.12-08-2011
20090169515Canine probiotic bifidobacteria globosum - According to the invention there is provided a strain of lactic acid bacteria of the species Bifidobacteria 07-02-2009
20090180987Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders - Methods for detecting a microorganism or cell in a subject and methods for detecting, imaging or diagnosing a site, disease, disorder or condition in a subject using microorganisms or cells and methods that microorganisms or cells for treating a disease, disorder or condition are provided. Sites, diseases and disorders include sites of cell proliferation, proliferative conditions, neoplasms, tumors, neoplastic disease, wounds and inflammation. Also provided are microorganisms and cells for use in the methods and compositions, combinations and kits, including diagnostic and pharmaceutical compositions, containing a microorganism or cell.07-16-2009
20110217266Genomic sequence of avian paramyxovirus type 2 and uses thereof - In this application is described the complete genomic sequence of avian parmyxovirus type 2, strains Yucaipa, England, Kenya and Bangor. The sequences are useful for production of recombinant infective virus, a virus vector, for vaccine development and for therapeutic compositions.09-08-2011
20110217267GENE THERAPY VECTORS AND CYTOSINE DEAMINASES - This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.09-08-2011
20090208461RECOMBINANT BACTERIA WITH E.COLI HEMOLYSIN SECRETION SYSTEM AND INCREASED EXPRESSION AND/OR SECRETION OF HLYA, PROCESS OF MANUFACTURING AND USES THEREOF - The invention relates to a recombinant bacterium with 08-20-2009
20090191157USE OF RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA) FOR THE TREATMENT OF TYPE 1 HYPERSENSITIVITY IN A LIVING ANIMAL INCLUDING HUMANS - The present invention relates to the use of a recombinant modified vaccinia virus Ankara (MVA) comprising a heterologous nucleic acid for the production of a medicament for the prevention and/or treatment of type I hypersensitivity in a living animal including humans. The invention further relates to a recombinant modified vaccinia virus Ankara (MVA) comprising a heterologous nucleic acid, wherein the heterologous nucleic acid is incorporated into a non-essential region of the genome of the MVA, the heterologous nucleic acid is under the control of, e.g. a vaccinia virus-specific promoter and, the heterologous nucleic acid is selected from the group of nucleic acids encoding an allergen selected from the group of weed pollens, grass pollens, tree pollens, mites, animals, fungi, insects, rubber, worms, human autoallergens, and foods.07-30-2009
20090130061Adenovirus vectors containing cell status-specific response elements and methods of use thereof - The present invention provides adenoviral vectors comprising cell status-specific transcriptional regulatory elements which confer cell status-specific transcriptional regulation on an adenoviral gene. A “cell status” is generally a reversible physiological and/or environmental state. The invention further provides compositions and host cells comprising the vectors, as well as methods of using the vectors.05-21-2009
20090130060Modified Vitamin K Dependent Polypeptides - The present invention relates to modified cDNA sequences coding for vitamin K-dependent polypeptides, in particular human Factor VII, human Factor VIIa, human Factor IX and human protein C and their derivatives with improved stability and extended plasma half life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.05-21-2009
20090162320GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA VIRUS SPIKE PROTEIN - The present inventors successfully introduced genes into stem cells of airway epithelial tissues using simian immunodeficiency virus vectors pseudotyped with F and HN, which are envelope glycoproteins of Sendai virus. Gene transfer into airway epithelial tissue stem cells using a vector of the present invention is useful for gene therapy of genetic respiratory diseases such as cystic fibrosis. Furthermore, it is possible to select respiratory organs such as the lungs as production tissues for providing proteins that are deficient due to genetic diseases.06-25-2009
20090148411VIRAL VECTOR-BASED GENE THERAPY METHODS AND COMPOSITIONS - Disclosed are improved VP2-modified recombinant adeno-associated viral (rAAV) vectors, expression systems, and rAAV virions that are fully virulent, yet lack functional VP2 protein expression. Also disclosed are pharmaceutical compositions, virus particles, host cells, and pharmaceutical formulations that comprise these modified vectors useful in the expression of therapeutic proteins, polypeptides, peptides, antisense oligonucleotides and/or ribozymes in the cells and tissues of selected mammals, including, for example, human tissues and host cells.06-11-2009
20090148409CANINE PROBIOTIC BIFIDOBACTERIA GLOBOSUM - According to the invention there is provided a strain of lactic acid bacteria of the species 06-11-2009
20100266546SELECTIVELY REPLICATING VIRAL VECTORS - The present invention provides recombinant viruses which replicate the viral genome selectively in response to the intracellular conditions of the target cell through the use a pathway-responsive promoter which substantially inhibits viral replication in the host cell based on the phenotypic or genotypic of the infected cell. In the target cell, the promoter element of the pathway-responsive promoter is inactive and thus the virus is permitted to replicate. This results in: (1) killing the cells by natural lytic nature of the virus, and/or (2) provides a therapeutic dose of a transgene product (amplified in comparison to replication incompetent vectors) to the target cell, and (3) producing a localized concentration of the virus facilitating the infection of surrounding cells to the recombinant virus. The invention further provides therapeutic and diagnostic methods of use of the vectors, pharmaceutical formulations comprising the vectors, methods of making the vectors and transformed cells comprising the vectors.10-21-2010
20120141420TARGETED DELIVERY OF G-CSF FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS - The present invention relates to a method of treating Amyotrophic Lateral Sclerosis by the targeted delivery of granulocyte-colony stimulating factor to the central nervous system with an adeno-associated virus (AAV) vector.06-07-2012
20100143302Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof - The present application relates to recombinant adenoviruses, more in particular those that encounter low levels of pre-existing neutralizing activity in hosts that are in need of treatment or vaccination. Particularly, the invention relates to recombinant vectors derived from two subgroup D adenoviruses: Ad26 and Ad48.06-10-2010
20120237481Incorporation of the B18R gene to enhance antitumor effect of virotherapy - The present invention relates to a novel composition and method to potentiate the antitumor effect of an oncolytic virus by providing for resistance against a host's innate interferon response. Particularly, a B18R gene is incorporated into an oncolytic virus. During treatment of a host with the modified oncolytic virus, the oncolytic virus retains its phenotype, and the host's innate immune response has a minimal affect on viral replication.09-20-2012
20100143305TREATMENT OF HIV AND AIDS USING PROBIOTIC LACTOBACILLUS REUTERI - A method for treating or preventing a Human Immunodeficiency Virus (HIV) infection, or treating or preventing Acquired Human Immunodeficiency Syndrome (AIDS), in a subject in need thereof, is disclosed. The method involves colonizing a genetically modified probiotic 06-10-2010
20090087413SELF-COMPLEMENTARY AAV-MEDIATED DELIVERY OF INTERFERING RNA MOLECULES TO TREAT OR PREVENT OCULAR DISORDERS - The invention provides methods for delivering interfering RNA molecules to an eye of a patient to treat ocular disorders. In particular, the methods of the invention comprise the use of a self-complementary adeno-associated (scAAV) viral vector that can deliver an interfering RNA molecule to an eye of a patient to inhibit expression of a gene that is associated with an ocular disorder.04-02-2009
20090087412Methods and compositions relating to HDAC 4 and 5 regulation of cardiac gene expression - The present invention relates to cardiac hypertrophy. More particularly, the present invention defines the molecular events linking calcium stimulation to cardiac hypertrophy. More specifically, the present invention shows that Ca04-02-2009
20100098664Lentiviral vectors allowing RNAi mediated inhibition of GFAP and vimentin expression - The present invention relates to method for preventing, treating or alleviating a central nervous system (CNS) disorder using a non replicative lentivirus comprising a lentiviral genome comprising a nucleic acid sequence producing at least one functional miRNA, at least one functional shRNA and/or at least one functional siRNA, preferably derived from said shRNA, said miRNA, shRNA or siRNA being designed to silence the expression of a gene that encodes a protein of the astrocyte cytoskeleton. The present invention further relates to compositions and kits comprising such a lentivirus as well as to uses thereof.04-22-2010
20100080775RECOMBINANT ADENOVIRUSES ENCODING THE SPECIFIC IODINE TRANSPORTER (NIS) - The present invention relates to the field of gene therapy and the treatment of tumors.04-01-2010
20100098666Humanized Viral Vectors and Methods of Use Thereof - The present invention provides humanized viral vectors and methods of use thereof for delivery of transgenes or therapeutic nucleic acids to human subjects. Humanized viral vectors are modified from known viral vectors such as those based on AAV by coating their surface with a human protein such as human serum albumin and optionally a lipid coating or formulation, so that the foreign or non-human nature of the vector is masked. The coating is performed in a manner that reduces or prevents binding of antibodies to the vector surface, thereby reducing or preventing antibody-mediated clearance of vector, but still allowing the vector to transduce target cells and achieve therapeutic gene transfer. Such humanized vectors therefore evade pre-existing immune surveillance, reduce immune responses, and achieve therapeutic gene transfer in the presence of pre-existing antibodies to the viral vector.04-22-2010
20100124546Adenovirus With Mutations in the Endoplasmic Reticulum Retention Domain of the E3-19K Protein and Their Use in Cancer Treatment - The present invention relates to an adenovirus wherein said adenovirus replicates and it contains a mutation in the endoplasmic reticulum retention domain of E3-19K, and to the use of said mutant in treating cancer. Said mutant virus may also contain other mutations and insertions of DNA sequences used to confer selectivity and antitumor potency. The invention has application in the field of cancer therapy.05-20-2010
20130216500METHOD OF TREATING OR RETARDING THE DEVELOPMENT OF BLINDNESS - A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.08-22-2013
20090202492ADENOVIRUS VACCINE UTILIZING IKK AS ADJUVANT - The invention provides an adenovirus that expresses a constitutively activated form of human NF-κB activating kinase (IKK). Co-administration of the adenovirus expressing the constitutively activated form of IKK (Ad-IKKβ) and an antigen confers an enhanced immune response against the antigen relative to co-administration of the antigen and adenovirus that do not express IKK. Optionally, the adenovirus comprises one or more heterologous nucleic acid sequences that may encode, for example, a biologically active product such as the antigen of an infectious agent (e.g., bacterial, fungal, etc.) or a tumor antigen. Accordingly, the adenovirus is useful for inducing desired immune responses such as those against infectious agents and cancer cells.08-13-2009
20090202488Use Of The Foamy Virus Bet Protein For Inactivating APOBEC - Described is the foamy virus Bet-mediated inactivation of the mutagenic, genome-modifying and vector-inactivating cellular enzyme ABOBEC. Such inactivation is useful for the treatment or prevention of various diseases, e.g., cancer, or for enhancing the production and genetic stability of gene therapy vectors, preferably retroviral vectors.08-13-2009
20090004146Humanised Baculovirus - A genetically engineered baculovirus which is engineered to target therapeutic agents to cells, typically cancer cells, for example prostate cancer cells.01-01-2009
20080206199Chimeric Herpes Viruses and Uses Thereof - Disclosed herein are chimeric herpesviruses as well as methods of making and using such chimeric herpesviruses. The chimeric viruses comprise two nucleic acid sequences, one from a herpesvirus and one from a different virus. The herpesvirus nucleic acid sequence is a modified protein kinase R (PKR) evasion gene. The second viral nucleic acid sequence inhibits PKR-mediate protein shutoff in tumor cells, but is not neurovirulent. Thus, the chimeric virus has reduced neurovirulence as compared to the wild-type herpesvirus but remains replication competent.08-28-2008
20080206198Compounds and methods for pharmico-gene therapy of epithelial sodium channel associated disorders - Agents and methods to alter epithelial sodium channel (ENaC) activity.08-28-2008
20090274659Compositions And Methods For Producing Fermentation Products And Residuals - The present invention provides compositions and methods designed to increase value output of a fermentation reaction. In particular, the present invention provides a business method of increasing value output of a fermentation plant. The present invention also provides a modified fermentation residual of higher commercial value. Also provided in the present invention are complete animal feeds, nutritional supplements comprising the subject ferment residuals. Further provided by the present invention is a method of performing fermentation, a modified fermentative microorganism and a genetic vehicle for modifying such microoganism.11-05-2009
20090280089Inhibition of the liver tropism of adenoviral vectors - The invention relates to the inhibition of liver tropism of adenoviral vectors, by replacement of the endogeneous HVR5 of hexon protein of said adenoviral vector with an heterologous polypeptide.11-12-2009
20090104155TREATMENT OF CONNECTIVE TISSUE DISORDERS - The present invention relates to methods of delivering nucleic acids to connective tissue cells and to methods of treating connective tissue disorders; in particular, the invention provides methods of delivering nucleic acids to connective tissue cells and methods of treating connective tissue disorders using parvovirus vectors.04-23-2009
20090104156PHARMACEUTICAL COMPOSITIONS FOR TREATING PAPILLOMAVIRUS TUMORS AND INFECTION - A pharmaceutical composition for treating or preventing a papillomavirus infection or tumour, including, as the therapeutical agents, a polypeptide from an early region and a polypeptide from a late region of a papillomavirus, optionally combined with a polypeptide having immunostimulatory activity or a polypeptide from an early or late region of a papillomavirus and a polypeptide having immunostimulatory activity, or alternatively, a recombinant vector containing inserted DNA fragments coding for the above-mentioned polypeptide combinations.04-23-2009
20090104154Composition and method for killing of tumours - The present invention provides a method of treating a solid tumour in a subject, the method comprising the following steps (i) delivering to the solid tumour a composition comprising an engineered ovine atadenovirus; and (ii) administering a prodrug to the subject, wherein the engineered ovine atadenovirus comprises a promoter and a gene encoding an enzyme which converts the prodrug to a cytotoxic metabolite, the gene being under control of the promoter.04-23-2009
20090104153METHOD OF ELICITING IMMUNE RESPONSE - The present invention relates to methods of eliciting an immune response by use of a prime-boost schedule for delivering a polynucleotide encoding a heterologous non-self antigen. In particular, the invention relates to a prime-boost schedule wherein the priming polynucleotide composition is delivered by an adenoviral vector, and the boosting polynucleotide composition is coated on or incorporated in a particle and is administered by a particle acceleration device.04-23-2009
20090285784DSRNA As Insect Control Agent - The present invention concerns methods for controlling insect infestation via RNAi-mediated gene silencing, whereby the intact insect cell(s) are contacted with a double-stranded RNA from outside the insect cell(s) and whereby the double-stranded RNA is taken up by the intact insect cell(s). In one particular embodiment, the methods of the invention are used to alleviate plants from insect pests. Alternatively, the methods are used for treating and/or preventing insect infestation on a substrate or a subject in need of such treatment and/or prevention. Suitable insect target genes and fragments thereof, dsRNA constructs, recombinant constructs and compositions are disclosed.11-19-2009
20090285783Methods and compositions for cancer therapy using a novel adenovirus - The invention comprises a novel virus that can kill mammalian cancer cells efficiently. The virus produces a novel protein that converts two non-toxic prodrugs into potent chemotherapeutic agents. These chemotherapeutic agents are produced locally and help the virus kill the cancer cells as well as sensitize them to radiation. In preclinical studies, the virus has proven effective at killing a variety of mammalian cancer cells either alone or when combined with prodrug therapy and/or radiation therapy. The invention may provide a safe and effective treatment for human cancer.11-19-2009
20080213224Immunoglobulin against helicobacter pylori - The present invention relates to materials and methods for prevention, treatment and diagnosing of infections caused by 09-04-2008
20080213223Systemic viral/ligand gene delivery system and gene therapy - The present invention relates to gene transfer and gene therapy technology. More specifically, the invention provides compositions and methods for targeted virus delivery. The method utilizes a method of mixing the virus, which may be a recombinant virus which will express a protein of interest or a nucleic acid of interest, with a cell-targeting ligand, e.g., transferrin. The virus and ligand are mixed without crosslinkers or agents which would covalently bond the virus and ligand. This simple mixing causes less inactivation than chemically linking the ligand to the virus and therefore results in a more active therapeutic composition than obtained by methods which utilize crosslinking agents.09-04-2008
20080213222Methods And Compositions For Use In Gene Therapy for Treatment of Hemophilia - The invention includes a composition comprising a recombinant adeno-associated viral vector comprising at least two adeno-associated virus inverted terminal repeats, a promoter/regulatory sequence, isolated DNA encoding Factor IX and accompanying 5′ and 3′ untranslated regions and a transcription termination09-04-2008
20080213221Compounds and methods to enhance rAAV transduction - Agents and methods to alter rAAV transduction are provided.09-04-2008
20100143304ADENOVIRAL VECTOR COMPRISING HERPES SIMPLEX VIRUS TYPE 1 THYMIDINE KINASE AND A TRANSGENE FOR INCREASING THE EXPRESSION OF THE TRANSGENE - Compositions and methods useful in transgene expression are provided. Herpes simplex virus type 1 thymidine kinase sequences (“TK sequences”) are used to enhance transgene expression in first generation and high capacity adenoviral vectors. An mCMV promoter-driven β-galactosidase-expressing cassette is combined with TK sequences through direct fusion of the cDNA's. β-galactosidase (transgene) expression is enhanced independent of adenoviral vector selection. Methods of enhancing transgene expression employing the inventive adenoviral vectors are provided, along with pharmaceutical preparations comprising the inventive vectors and kits for enhanced transgene expression.06-10-2010
20090169516METHOD OF CONSTRUCTING GENE TRANSPORT SUPPORT - An object of the present invention is to provide a method of efficiently constructing a gene delivery carrier having a favorable activity and expression efficiency of a protein expressed by a gene introduced by transformation. Moreover, an object of the present invention is to provide a pharmaceutical composition comprising a gene delivery carrier constructed by the construction method and a therapeutic agent for solid tumor comprising the resistant bacterium. The objects of the present invention have been attained by a gene delivery carrier consisting of an anaerobic microorganism capable of growing in a tumor tissue in an anaerobic environment and capable of expressing (A) a protein having an antitumor activity or (B) a protein having an activity of converting an antitumor substance precursor to an antitumor substance, wherein DNA encoding the protein of interest is allowed to further comprise, on the 5′-terminal side thereof, a DNA fragment comprising a nucleotide sequence encoding a peptide consisting of an amino acid sequence from the 1st to at least 4th amino acids at the N-terminus of a histone-like DNA-binding protein.07-02-2009
20090169513Expression of virus entry inhibitors and recombinant AAV therefor - The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver genes encoding human immunodeficiency virus entry inhibitors to target cells in mammals.07-02-2009
20080241103Recombinant Virus Comprising an Intact Tumor-Therapeutic Antibody With Human Constant Regions and the Use Thereof - The present invention provides a recombinant virus containing a nucleotide sequence encoding a tumor-therapeutic full-length antibody with human constant regions, and uses thereof. After a nucleotide sequence of a gene encoding a tumor-therapeutic full-length antibody with human constant regions of the light chain and the heavy chain is inserted into the genome of a recombinant virus, the tumor-therapeutic full-length antibody with human constant regions can be efficiently expressed in tumor cells, thereby inhibit the growth and metastasis of tumors.10-02-2008
20090297480TREATING GLAUCOMA, CARDIOVASCULAR DISEASES, AND RENAL DISEASES - This document provides methods and materials related to treating glaucoma, ocular hypertension, cardiovascular diseases, and renal diseases. For example, this document provides isolated nucleic acid molecules and viral vectors (e.g., lentiviral vectors) containing isolated nucleic acid molecules. Methods for reducing intraocular pressure as well as symptoms and progression of cardiovascular and renal diseases also are provided.12-03-2009
20080233086Expression Vectors for Treating Bacterial Infections - The present invention is compositions and methods for producing anti-bacterial polypeptides, and for using those compositions and methods for treating diseases and conditions caused by a bacterial infection. More specifically, the compositions and methods include treating a gram-negative bacterium with a gram-positive host that produces a polypeptide effective against the gram-negative bacterium.09-25-2008
20080274083Antiviral Resistance Mutants and Applications Thereof - The present invention relates generally to viral variants exhibiting reduced sensitivity to agents such as nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.11-06-2008
20080286239COMBINED TUMOR SUPPRESSOR GENE THERAPY AND CHEMOTHERAPY IN THE TREATMENT OF NEOPLASMS - In one embodiment, this invention provides methods of treating mammalian cancer or hyperproliferative cells, said method comprising contacting said cells with a tumor suppressor protein or tumor suppressor nucleic acid and also contacting said cell with at least one adjunctive anti-cancer agent. The invention also provides for a pharmacological composition comprising a tumor suppressor protein or a tumor suppressor nucleic acid and at least one adjunctive anti-cancer agent, and a kit for the treatment of mammalian cancer or hyperproliferative cells.11-20-2008
20080286236INHIBITION OF YERSINIA PESTIS - The disclosure relates to the targeting of 11-20-2008
20080292592Oncolytic Adenovirus Armed with Therapeutic Genes - The present invention involves compositions and methods for treating preventing cancer using compositions including replication competent adenovirus. The application competent adenovirus may or may not encode a therapeutic polynucleotide.11-27-2008
20080292594MUTANT REOVIRUSES AND METHODS OF MAKING AND USING - Provided herein is a mutant reovirus (e.g., a genetically-engineered ISVP). Compositions including mutant reoviruses and methods of using such mutant reoviruses are also provided.11-27-2008
20080292595AAV vectors for gene delivery to the lung - Methods of making and using recombinant AAV vectors and virions for gene delivery to the lung are described. The recombinant AAV virions are derived from caprine AAV and bovine AAV, both of which display tropism for lung tissue.11-27-2008
20080311080BIFIDOBACTERIUM IN THE TREATMENT OF INFLAMMATORY DISEASE - A strain of 12-18-2008
20080213220Cancer-targeted viral vectors - The present invention relates to viral vectors that are targeted to cancer cells. The viral vectors of the invention are adenoviruses having a PEG-3 promoter driving the expression of the viral genes E1A and E1B. The PEG-3 promoter exhibits increased activity in malignant cells. Adenoviruses of the invention show increased replication in malignant cells, thereby producing a cytopathic effect. The viral vectors of the invention further comprise additional genes of interest, and/or may have altered capsid proteins that may enhance infection of and/or target infection to cancer cells. Additional cell types derived from diseased states in which the PEG-3 promoter is selectively active are also therapeutic targets of the viral vectors of the instant invention including those generating allergic, autoimmune and inflammatory responses.09-04-2008
20090004145COMPOSITIONS AND METHODS INVOLVING GENE THERAPY AND PROTEASOME MODULATION - The present invention concerns the methods and compositions involving a therapeutic polypeptide, such as a tumor suppressor or a nucleic acid encoding such in combination with a proteasome inhibitor, for the treatment of cancer. In certain examples, a treatment for ovarian cancer is provided.01-01-2009
20110206640ENGINEERED SYNERGISTIC ONCOLYTIC VIRAL SYMBIOSIS - In one aspect, the invention provides methods for preferentially killing target proliferating cells in a host, such as cancer cells, by infecting host tissues with two or more strains of virus. The strains of virus may be selected to provide a synergistic and symbiotic effect, involving a contemporaneous lytic infection in the target proliferating cells. In selected embodiments, the viruses are selected so that expression of a first virulence factor in proliferating cells infected with the first virus increases the lytic effect of the second virus; and, expression of the second virulence factor in proliferating cells infected with the second virus increases the lytic effect of the first virus. The genomes of the first and second viruses may be selected so that they are incompatible for recombination between the viral genomes in cells of the host.08-25-2011
20120034189MEANS AND METHODS FOR DURABLE INHIBITION OF PATHOGENS - The invention provides improved nucleic acids for anti-HIV therapy. The invention further provides selection methods which are capable of predicting already at an early stage of development whether promising anti-pathogenic candidate compounds will be suitable for therapeutic use in vivo.02-09-2012
20080286238Recombinant Adenovirus Expressing A Gene Encoding Streptolysin O Proetin and Anti-Cancer Composition Comprising Same - A recombinant adenovirus expressing a streptolysin O (SLO) protein comprising a SLO gene; a promoter operably linked to the SLO gene; a polyadenylation signal sequence; and an adenovirus genome lacking E1 gene effectively kills a cancer cell by expressing a pore-forming toxin, SLO protein, and, therefore, is useful for the suicide cancer gene therapy.11-20-2008
20110027231METHOD FOR THE RANDOM DIVERSIFICATION OF A GENETIC SEQUENCE WHILE PRESERVING THE IDENTITY OF SOME INNER SEGMENTS OF SAID GENETIC SEQUENCE - The invention relates to a method for obtaining a variety of recombinant bacteriophages in which the screening proteins have been modified by the insertion in their genetic sequence of randomly produced oligonucleotides, and to bacteriophages banks that can be obtained according to said method.02-03-2011
20090180988Id-1 and Id-2 Genes and Products as Therapeutic Targets for Treatment of Breast Cancer and Other Types of Carcinoma - A method for treatment and amelioration of breast, cervical, ovarian, endometrial, squamous cells, prostate cancer and melanoma in a patient comprising targeting Id-1 or Id-2 gene expression with a delivery vehicle comprising a product which modulates Id-1 or Id-2 expression.07-16-2009
20090123427Method of Treating a Malignancy in a Subject and a Pharmaceutical Composition for Use in Same - There is a disclosed a method of killing abnormal cells such as malignant cells including melanoma cells, using a virus recognising at least one of a cell adhesion molecule and a complement regulatory protein. The virus may be a member of the Picornaviridae family. Coxsackie A-group viruses have been found to be particularly suitable. The cell adhesion molecule is desirably a member of the immunoglobulin (Ig) superfamily. Typically, the complement regulatory protein will be DAF.05-14-2009
20090123426Compositions for Bacterial Mediated Gene Silencing and Methods of Using the Same - Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating cancer off cell proliferative disorders. The bacterium includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells.05-14-2009
20100272688METHOD OF TREATING OR RETARDING THE DEVELOPMENT OF BLINDNESS - A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.10-28-2010
20110206639REPLICATION COMPETENT VIRUSES CAPABLE OF SILENCING VIRUS INHIBITORY FACTOR EXPRESSION - Described is a replication competent virus, being capable to replicate and having lytic capacity in host cells, the virus comprising in the genome thereof, at least one DNA sequence coding for a silencing factor functional in reducing expression of a target gene in the said host cells, operably linked to one or more expression control sequences, functional in the said host cells, and the use thereof in the preparation of a medicament and to the use thereof in a method for lysing host cells expressing a virus inhibitory factor.08-25-2011
20100150872POLYPEPTIDES DERIVED FROM THE HEMOPEXIN-LIKE DOMAIN OF METALLOPROTEINASE MMP-2 - The present invention relates to anti-angiogenic polypeptides derived from the non catalytic C-terminal hemopexin-like domain of the metalloproteinase MMP-2. The invention also provides pharmaceutical compositions comprising said anti-angiogenic polypeptides and methods for using said polypeptide for treating angiogenic diseases, and in particular for treating cancer.06-17-2010
20090186003HERPES SIMPLEX VIRUS EXPRESSING FOREIGN GENES AND METHOD FOR TREATING CANCERS THEREWITH - An anti-cancer pharmaceutical composition includes a herpes simplex virus (HSV) vector into which a nucleic acid sequence encoding for an anti-cancer agent selected from interleukin-12, GM-CSF, and CD has been inserted. A method of treatment of a patient suffering from cancer includes administering to the patient the anti-tumor pharmaceutical composition including a HSV vector having a nucleic acid sequence encoding for an anti-cancer agent selected from interleukin-12, GM-CSF, and CD inserted therein.07-23-2009
20090186002rAAV-delivered alpha-1-antitrypsin compositions and method for the treatment and prevention of diabetes - The subject invention concerns materials and methods for gene therapy. One aspect of the invention pertains to vectors which can be used to effect genetic therapy in animals or humans having genetic disorders where expression of high levels of a protein of interest are required to treat or correct the disorder. The subject invention also pertains to methods for treating animals or humans in need of gene therapy to treat or correct a genetic disorder. The materials and methods of the invention can be used to provide therapeutically effective levels of a protein that is non-functional, or that is absent or deficient in the animal or human to be treated. In one embodiment, the materials and methods can be used to treat alpha-1-antitrypsin deficiency.07-23-2009
20090136453Methods for treating pain - Methods of treating pain by delivery of anti-inflammatory cytokines, proinflammatory cytokine antagonists, and agents that act to reduce or prevent proinflammatory cytokine actions, to the nervous system are described. These agents can be delivered using gene therapy techniques. Alternatively, the agents can be delivered in protein compositions.05-28-2009
20090136452TARGETING OF HERPES SIMPLEX VIRUS TO SPECIFIC RECEPTORS - The invention relates to engineered Herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a selected receptor, the HSV particles of the invention are useful for targeting cells that express the selected receptor, which itself may be a product of genetic engineering. The ability to selectively target cells render the HSV particles. particularly useful in selectively diagnosing, treating, and imaging cells bearing the selected binding pair member, such as a receptor. The invention also provides for polynucleotide-based therapy to cells bearing the selected binding pair member such as a receptor.05-28-2009
20130216499COMPOSITIONS OF RECOMBINANT HUMAN ENDOSTATIN ADENOVIRUS INJECTIONS AND METHODS OF PRODUCTION - The invention generally relates to compositions of and methods for production of recombinant adenoviruses that carry therapeutic genes. More particularly, the invention relates to lyophilized recombinant adenoviruses injection and its related production procedures, including production procedures for the recombinant adenovirus vectors (or other viral vectors) that carry the genes of human endostatins.08-22-2013
20130216501THERAPEUTIC METHODS BASED ON TYROSINE-SUBSTITUTED, CAPSID-MODIFIED RAAV VECTORS - Disclosed are tyrosine-modified rAAV vectors, as well as infectious virions, compositions, and pharmaceutical formulations that comprise them. Also disclosed are methods of preparing and methods for using the disclosed tyrosine-phosphorylated capsid protein mutant rAAV vectors in a variety of diagnostic and therapeutic applications including in vivo and ex vivo gene therapy, and large-scale production of rAAV vectors.08-22-2013
20080317717ANTI-HEPATITIS B VIRUS RIBOZYMAL NUCLEIC ACID - This invention relates to ribozymes which cleave Hepatitis B Virus (HBV) at CUC sites. Suitable ribozymes may, for example, cleave at GGCUCUCUCGUCCC, CCUCAGCUCUGUAUCG or GAGGACUCUUGGA recognition sequences in HBV RNA. Ribozymal DNA, vector systems and pharmaceutical compositions are provided which may be useful, for example, in the treatment of HBV infection.12-25-2008
20080317716Fusion proteins of mycobacterium tuberculosis - The present invention relates to compositions and fusion proteins containing at least two 12-25-2008
20090252707NOVEL EXPRESSION VECTORS AND USES THEREOF - A method for treating an HIV disease in a subject in need of said treatment, comprising administering to the subject a therapeutically effective amount of a DNA vaccine comprising an expression vector and a pharmaceutically acceptable excipient, where the expression vector comprises: (a) a heterologous promoter operatively linked to a DNA sequence encoding a nuclear-anchoring protein, where the nuclear-anchoring protein comprises: (i) a DNA binding domain which binds to a specific DNA binding sequence, and (ii) a functional domain of the Bovine Papilloma Virus Type 1 E2 protein, where the functional domain binds to a nuclear component; (b) a multimerized DNA sequence that forms a binding site for the nuclear anchoring protein; and (c) at least one expression cassette comprising a DNA sequence encoding a protein or peptide that stimulates an immune response specific to the protein or peptide; where the expression vector lacks an origin of replication functional in mammalian cells.10-08-2009
20130121966Generation of PSA-only producing mutant strain - Provided is an isolated 05-16-2013
20130121967BACTERIOPHAGES FOR USE AGAINST BACTERIAL INFECTIONS - The present invention relates to a composition comprising obligate lytic bacteriophages generated by a method comprising subjecting normally in vivo lysogenic, pseudolysogenic or temperate bacteriophages to genetic modifications in vitro, which alters the biological activity of one or more of the individual gene products for establishing, maintaining, controlling or regulating the lysogenic life cycle of the bacteriophages, thereby converting them to obligate lytic bacteriophages, wherein the genetic modification includes modification of a single gene in the operon containing a gene resulting in a gene product for establishing, maintaining, controlling or regulating the lysogenic life cycle of the bacteriophages.05-16-2013
20090142302INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 7 FOR TREATMENT OF CANCER - Methods of treating a tumor in a subject include identifying a subject having, at risk for, or suspected of having a tumor, and administering to the subject an effective amount of an IGFBP7 agent if the tumor has increased Ras-BRAF-MEK-Erk signaling, is dependent for growth and/or survival upon the Ras-BRAF-MEK-Erk signaling pathway, and/or expresses an activated or oncogenic BRAF or RAS.06-04-2009
20090208459Methods of treating anemia using recombinant adeno-associated virus virions - The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue in the treatment of anemia is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of a delivered nucleotide sequence encoding erythropoietin, and for in vivo secretion thereof from transduced muscle cells such that systemic delivery is achieved.08-20-2009
20110223135SIMIAN ADENOVIRUSES SAdV-43, -45, -46, -47, -48, -49, AND -50 AND USES THEREOF - A recombinant vector comprises simian adenovirus 43, 45, 46, 47, 48, 49 or 50 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus 43, 45, 46, 47, 48, 49 or 50 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.09-15-2011
20090130062Novel Application of Heparin-Binding Epidermal Growth Factor-Like Growth Factor for Medical Purposes - The present invention provides an agent for protecting the liver and/or promoting liver regeneration, which contains a heparin-binding EGF-like growth factor-like growth factor (HB-EGF) or a partial peptide thereof, or a nucleic acid that encodes same, and an agent for the prophylaxis or treatment of liver diseases. The present invention further provides a method for producing a cell for liver protection and/or promoting liver regeneration, and for the prophylaxis/treatment of a liver disease, which includes introducing a nucleic acid that encodes HB-EGF or a partial peptide thereof into a cell collected from an animal.05-21-2009
20090081166Colonization factor (CF) antigens of enterotoxigenic escherichia coli in recombinant bacteria - strains, such as enterotoxigenic 03-26-2009
20090098087METHOD OF TREATING LACTOSE INTOLERANCE USING GENETICALLY ENGINEERED BACTERIA - The present invention relates to genetically engineered bacteria that are able to colonize the mammalian intestine and actively produce mammalian lactase (lactose-phlorizin hydrolase or LPH). This lactose-digesting enzyme is stable and active under the conditions normally found in the mammalian small intestine. Experimental subjects colonized with the genetically engineered bacteria show improved ability to digest lactose in dairy foods.04-16-2009
20110229439COMPLEMENT PROTEINS - The present invention relates to classical pathway complement proteins and their use in the prognosis and prevention of diseases involving cone photoreceptor degeneration. Specifically, the present invention is directed to the use of one or more classical pathway complement proteins, preferably involved in the recognition phase, in the maintenance of cone photoreceptor cell viability in a degenerating retina. The invention is also directed to a method for determining the susceptibility, risk of development and/or progression of diseases involving cone photoreceptor degeneration in a subject.09-22-2011
20090208460Mutant Herpes Simplex Viruses Comprising Nucleic Acid Encoding A Nitroreductase - An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a nitroreductase (NTR) is disclosed. Disclosed herpes simplex viruses are indicated to be useful in the treatment of cancer which may involve gene directed enzyme prodrug therapy.08-20-2009
20090148410CANINE PROBIOTIC BIFIDOBACTERIA PSEUDOLONGUM - According to the invention there is provided a strain of lactic acid bacteria of the species Bifidobacteria 06-11-2009
20090004144Recombinant Adeno-Associated Virus Vector for Treatment of Alzheimer Disease - Disclosed is an adeno-associated virus vector capable of expressing a peptide fragment containing a humoral immunity induction site of the β-amyloid peptide, comprising DNA encoding the peptide fragment in an operative form.01-01-2009
20090202493MIR-150 FOR THE TREATMENT OF BLOOD DISORDERS - The invention provides methods of treating certain blood related disorders, in particular, thrombocytopenia and anemia comprising increasing miR-150 expression or inhibiting miR-150 in progenitor cells respectively.08-13-2009
20090208458Transcriptional inhibitor for human k-ras gene - A transcriptional inhibitor for human K-ras gene which comprises one or more proteins selected from the group consisting of a protein having the amino acid sequence represented by SEQ ID NO:1, a protein having an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:1 by substitution, deletion or addition of one to several amino acids and having an activity of inhibiting the transcription of human K-ras gene, and partial fragment proteins thereof having an activity of inhibiting the transcription of human K-ras gene. This transcriptional inhibitor for human K-ras gene specifically inhibits the transcription and expression of K-ras gene, which is an oncogene, in a human cancer cell. Thus, it can inhibit the proliferation of cancer cells and induce the reversion of cancer cells into normal cells, which makes it usable as an anticancer agent with little side effects on normal cells.08-20-2009
20090246175THERAPEUTIC USE OF SCIN, A STAPHYLOCOCCAL COMPLEMENT INHIBITOR IN INFLAMMATORY DISEASES - The present invention relates to the use of the staphylococcal complement inhibitor (SCIN) or a homologue thereof, or a derivative or a fragment of SCIN or the SCIN homologue for the preparation of a medicament for intervening with C3 and C5 convertases. The medicament is in particular intended for inhibiting activation of the classical and/or the alternative pathway of complement. More in particular, the medicament is for treating indications that involve complement activation via the classical and/or alternative pathway.10-01-2009
20090220458PSEUDOTYPED RETROVIRAL VECTORS AND METHODS OF USE THEREOF - The present invention provides nucleic acids encoding recombinant envelope proteins; and packaging cells comprising the nucleic acids, which packaging cells provide for encapsidation of recombinant retroviral vectors. The present invention provides producer cells that produce pseudotyped recombinant retroviral vectors. The present invention further provides methods of purifying pseudotyped recombinant retroviral vectors; and purified pseudotyped recombinant retroviral vectors. The present invention further provides methods of delivering a gene product to an individual. The methods generally involve introducing a subject recombinant retroviral vector into an individual.09-03-2009
20090214478Method of treating ocular diseases by gene therapy - A method for the treatment of diseases associated with mutations in ABCA4 gene by administering, to a subject in need thereof, an adeno-associated viral vector encoding an ABCR protein; genetic constructs and adeno-associated viral vectors for use in this method.08-27-2009
20120195859RECOMBINANT PROBIOTIC BACTERIA FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD) AND IRRITABLE BOWEL SYNDROME (IBS) - The present invention relates to the general field of therapy of Inflammatory Bowel Disease (IBD) and/or Irritable Bowel Syndrome (IBS). Thus, the invention relates to a molecule selected from the trappin-2 protein or an active fraction thereof, a member of the WAP family proteins or an active fraction thereof or a member of the Serpin family proteins or an active fraction thereof for the treatment of Irritable Bowel Syndrome (IBS). The invention also relates to a recombinant food-grade bacterium comprising a gene selected from a gene coding for the trappin-2 protein or an active fraction thereof, a gene coding for a member of the WAP family proteins or an active fraction thereof, or a gene coding for a member of the Serpin family proteins or an active fraction thereof.08-02-2012
20090136451Humanised Baculovirus - We describe a modified baculovirus that has increased specific cell targeting and decreased non-specific targeting by mutation of a heparin sulphate binding motif.05-28-2009
20080299083Adenoviral vectors having a protein IX deletion - This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention.12-04-2008
20100266548LPS-Responsive CHS1/Beige-Like Anchor Gene and Therapeutic Applications Thereof - The present invention relates to a novel LPS-responsive and Beige-like Anchor gene (lrba), variants of the lrba gene, fragments of the lrba gene, and polypeptides encoded thereby. The subject invention also pertains to lrba interfering RNA, and uses thereof. In another aspect, the present invention also includes methods of inhibiting tumor growth in a patient by suppressing lrba function.10-21-2010
20080317715ANTI-BACTERIAL AGENTS - A method of killing bacteria before disease is caused in a mammal by applying a panel of bacteriophages on the mammal, wherein the panel comprises a first vir mutant bacteriophage mutated from a temperate prophage isolated from a first strain of bacteria, wherein the first vir mutant bacteriophage is infectious of the first strain of bacteria, and a second vir mutant bacteriophage mutated from a temperate prophage isolated from a second strain of bacteria, wherein the second v/r mutant bacteriophage is infectious of the second strain of bacteria wherein the first and the second strains of bacteria are the same species of bacteria in a pharmaceutically acceptable carrier; and killing the bacteria. A method of disinfection of a surface. A method of making surgical equipment. A method of treating milk and milk products. A method of identifying a bacteriophage suitable for killing a bacterium. A method of producing a panel of bacteriophages.12-25-2008
20120141419Biodegradable Linkers for Molecular Therapies - A method and a composition for delivery of a biomaterial to an animal cell or a tissue, the composition includes (a) a biomaterial; (b) a biodegradable cross-linker portion having a hydrolyzable bond, wherein the biodegradable cross-linker portion is covalently bound to the biomaterial; and (c) a substrate, wherein the substrate is covalently bound to the biodegradable cross-linker portion, provided that the biodegradable cross-linker is adapted to hydrolyze by breaking the hydrolyzable bond and thereby release and deliver the biomaterial. A process of making the composition is also provided.06-07-2012
20100178273METHODS AND COMPOSITIONS FOR TREATING MUCOSITIS - The invention relates generally to the field of mucositis. More particularly, the present invention relates to methods and compositions for treating and preventing mucositis. In particular for treating or preventing oral mucositis, especially stomatitis and esophagitis. The invention generally relates to the use of recombinant non-pathogenic and non-invasive microorganisms, in particular recombinant bacterium or yeast expressing a trefoil peptide in particular in combination with one or more factors that target the mucus, tight junctions or extracellular matrix and/or factors typically used in the treatment of mucositis.07-15-2010
20100183558SAFE LENTIVIRAL VECTORS FOR TARGETED DELIVERY OF MULTIPLE THERAPEUTIC MOLECULES - The present application discloses a lentiviral transfer system which includes: (i) a self-inactivating transfer vector comprising: multiple gene units, wherein each gene unit includes a heterologous nucleic acid sequence operably linked to a regulatory nucleic acid sequence; and (ii) a helper construct which lacks a 5′ LTR, wherein the 5′ LTR has been replaced with a heterologous promoter, in which the helper construct further comprises: a lentiviral env nucleic acid sequence containing a deletion, wherein the deleted env nucleic acid sequence does not produce functional env protein; and a packaging signal contains a deletion, wherein the deleted packaging signal is nonfunctional.07-22-2010
20100183556Recombinant expression vector system for variants of coagulation factor VIII and von Willebrand factor - Disclosed is an expression vector system for variants of coagulation factor VIII (FVIII) and von Willebrand factor (vWF). In detail, mutant vWF the size of which is significantly reduced by deleting exons but which has remarkably increased FVIII stabilizing and activating efficiency, and an expression vector system useful for the treatment of hemophilia which is capable of expressing the same along with FVIII are disclosed. Use of the mutant vWF with a reduced size enables effective expression of FVIII in a viral vector and significantly enhanced FVIII activity. Further, the viral vector may be effectively used to treat hemophilia through gene therapy.07-22-2010
20090117080Beta-Galactosidase with Transgalactosylating Activity - The present invention concerns a new β-galactosidase with transgalactosylating activity isolated from 05-07-2009
20100166708ANTIMICROBIAL AND ANTI-INFLAMMATORY THERAPIES AND COMPOSITIONS - The disclosure provides methods and compositions useful for treating microbial and viral infections. In certain aspects, the compositions and methods relate to the use of an effective amount of a delta-haemolysin and/or phenol soluble modulin-delta or functional variant thereof. In other aspects, the compositions and methods relate to the use of an effective amount of 07-01-2010
20100183557PTRA GENE AND USES THEREOF - An isolated nucleic acid molecule comprising a nucleotide sequence set forth in SEQ ID NO: 1, said nucleotide sequence encoding a protein inhibitory to 07-22-2010
20100254946MAINTENANCE OF HAIR GROWTH AND TREATMENT OF HAIR-LOSS - The present invention relates to a nucleic acid molecule, encoding a polypeptide having P2Y5 receptor function wherein said nucleic acid molecule comprises: (a) a nucleic acid molecule encoding a polypeptide having the amino acid sequence of SEQ ID NO:2; (b) a nucleic acid molecule having the DNA sequence of SEQ ID NO:1; (c) a nucleic acid molecule having the sequence of SEQ ID NO:1, wherein each thymidine is replaced by uridine; (d) a nucleic acid molecule that hybridizes under stringent conditions to the complementary strand of a nucleic acid molecule of (a), (b) or (c); (e) a nucleic acid molecule encoding a polypeptide having at least 80% sequence identity to the polypeptide of (a); or (f) a nucleic acid molecule that is degenerate with respect to the nucleic acid molecule of (b), (c) or (d); for the diagnosis, treatment and/or prevention of hair-loss and the diagnosis of a predisposition for hair-loss. Furthermore, the invention relates to compositions and uses for the diagnosis, treatment and/or prevention of hair-loss as well as to methods of identifying compounds useful in the treatment of hair-loss. The invention also relates to nucleic acid molecules carrying mutations that are causative and/or indicative of hair-loss, diagnostic compositions, kits and methods for testing for the presence of the mutant nucleic acid molecule.10-07-2010
20100239534Hybrid proteins that migrate retrogradely and transynaptically into the CNS - The non-toxic proteolytic C fragment of tetanus toxin (TTC peptide) has the same ability to bind nerve cells and be retrogradely transported through a synapse as the native toxin. A hybrid protein encoded by the IacZ-TTC gene fusion retains the biological functions of both proteins in vivo, i.e. retrograde transynaptic transport of the TTC fragment and β-gal enzymatic activity. After intramuscular injection, enzymatic activity could be detected in motoneurons and connected neurons of the brainstem areas. This strategy is useful for the delivery of a biological activity to neurons from the periphery to the central nervous system. Such a hybrid protein can also be used to map synaptic connections between neural cells.09-23-2010
20100226890Bacteriophage and their uses - There is provided a bacteriophage capable of lysing a 09-09-2010
20100254947SIMIAN SUBFAMILY B ADENOVIRUSES SAdV-28, -27, -29, -32, -33, AND -35 AND USES THEREOF - A recombinant vector comprises simian adenovirus 28, simian adenovirus 27, simian adenovirus 32, simian adenovirus 33, and/or simian adenovirus 35 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses one or more simian adenovirus-28, -27, -32, -33, or -35 genes is also disclosed. Methods of using the vectors and cell lines are provided.10-07-2010
20100233127TARGETED VECTORS FOR CANCER IMMUNOTHERAPY - This invention provides compositions and methods for treating cancer. More specifically this invention is directed to a targeted retroviral vector comprising a cytokine gene that can be administered either alone or in combination with a targeted retroviral vector comprising a cytocidal gene for treating cancer in a subject. Also provided are a kit or drug delivery system comprising the compositions for use in the methods described.09-16-2010
20120141418Treatment of Melanoma Using HSV Mutant - Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the γ34.5 gene in the long repeat region (R06-07-2012
20100209393Use of Polynucleotides Encoding Small Acid-Soluble Spore Protein for Inhibiting Bacterial Cell Growth and/or Treating Bacterial Infections - A polypeptide having α/β type SASP activity, for use as a medicament.08-19-2010
20100266547METHODS AND COMPOSITIONS FOR TREATMENT OF INTERFERON-RESISTANT TUMORS - The present invention provides a method for the treatment of interferon resistant tumors through the use of recombinant vectors encoding interferon species. In particular it is noted that interferon species provided by recombinant vectors possesses properties not associated with the recombinantly produced interferon proteins. The present invention further provides compositions useful in the treatment of interferon resistant tumors using recombinant vectors encoding interferons.10-21-2010
20090035279GENETIC VARIANTS ON CHR 15Q24 AS MARKERS FOR USE IN DIAGNOSIS, PROGNOSIS AND TREATMENT OF EXFOLIATION SYNDROME AND GLAUCOMA - The present invention relates to methods of diagnosing a susceptibility to an ocular disorder, including glaucoma and exfoliation syndrome. The invention provides methods of diagnosing an increased or decreased susceptibility to exfoliation syndrome and glaucoma, and methods for risk assessment, treatment and prognosis. The invention further relates to kits for use in the methods of the invention.02-05-2009
20100111904MATERIAL FOR CONTROL OF SOIL-BORNE DISEASE IN PLANT UTILIZING NOVEL FILAMENTOUS FUNGI - Disclosed is a novel filamentous fungus SD-F06 strain which can infect a root of a plant and grow symbiotically with the plant and is capable of controlling a soil-borne disease. Also disclosed is a material for controlling a soil-borne disease, which comprises a fungus body or fungal culture of a filamentous fungus SD-F06 strain. Further disclosed is a method for controlling a soil-borne disease in a plant by utilizing the material.05-06-2010
20120141421LIQUID VIRAL FORMULATIONS - Provided herein are liquid viral formulations useful for the stabilization and storage of viruses and methods of preparing these formulations. The liquid viral formulations described herein include a virus (e.g., a purified virus) and a non-viral composition including excipients and a liquid carrier. The formulations can be used, for example, to retain the infectivity or immunogenicity of viruses during periods of storage.06-07-2012
20120141422WIDESPREAD GENE DELIVERY TO THE RETINA USING SYSTEMIC ADMINISTRATION OF AAV VECTORS - The present invention relates to compositions and methods, in particular to methods based on systemic administration of scAAV, for delivering genes to cells of the retina of mammals, and in particular to photoreceptor cells, ganglion cells, glial cells, inner nuclear layer cells or cells of the retinal pigmented epithelium.06-07-2012
20090074724MATERIALS AND METHODS FOR INHIBITING WIP1 - Isolated or purified oligonucleotides and isolated or purified morpholino oligomers; a method of detecting cancer or a predisposition to cancer in a mammal, comprising comparing the level of expression of Wip1 in the mammal to a control; a method of treating cancer in a mammal that expresses the same or a higher level of Wip1 as compared to a mammal of the same species that does not have cancer, comprising administering to the mammal a cancer-treating effective amount of a Wip1 inhibitor; a method of screening an oligonucleotide or morpholino oligomer for the ability to inhibit the expression of Wip1; a method of determining the efficacy with which a test oligonucleotide or morpholino oligomer inhibits Wip1 expression; a method of screening a compound for Wip1-inhibiting activity; and a method of determining the efficacy with which a test compound inhibits Wip1.03-19-2009
20090074723Method of Treating or Retarding the Development of Blindness - A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.03-19-2009
20090257982 MEDICAL DEVICE FOR TREATING DIABETES MELLITUS, OBESITY, CHRONIC FATIGUE, AGING, AND OTHER MEDICAL CONDITIONS BY UTILIZING MODIFIED VIRUS VIRIONS TO INSERT MESSENGER RIBONUCLEIC ACID MOLECULES INTO CELLS - The common link between diabetes mellitus, obesity, chronic fatigue and even aging may be related to deficiencies involving a body's metabolism of glucose and the ability to optimally conduct the necessary biologic processes of aerobic respiration. Utilizing a medical device comprised of a modified form of virus to deliver to cells in the body the messenger RNA molecules needed to construct insulin receptors and generate the enzymes that participate in the processes of glycolysis, the tricarboxylic acid cycle, oxidative phosphorylation and anaerobic respiration will lead to greater utilization of blood glucose and a more efficient and sustained production of the energy molecules that fuel the metabolic processes of the cell. Greater utilization of blood glucose will significantly advance the effort to correct the medical problems associated with diabetes, obesity, chronic fatigue, and aging.10-15-2009
20090257983MEDICAL TREATMENT DEVICE FOR TREATING AIDS BY UTILIZING MODIFIED HUMAN IMMUNODEFICIENCY VIRUS VIRIONS TO INSERT ANTI-VIRAL MEDICATIONS INTO T-HELPER CELLS - The medical device by which a modified Human Immunodeficiency Virus or virus-like structure is used as a transport medium to carry a payload of a quantity of anti-viral drug molecules to T-Helper cells in the body. The modified Human Immunodeficiency Virus or virus-like structure makes contact with a T-Helper cell by means of the modified virus's exterior probes or virus-like structure's exterior probes. Once the exterior probes engage the T-Helper cell's receptors, the modified virus or virus-like structure inserts into the T-Helper cell the quantity of medically therapeutic anti-viral drug molecules it is carrying. The anti-viral drug molecules exhibit an anti-viral effect when present inside the T-Helper cells thus assisting in repelling an infection by the Human Immunodeficiency Virus and the use of such a device significantly lowers the occurrence of unwanted deleterious side effects.10-15-2009
20090257981Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same - Recombinant viruses comprising a heterologous DNA sequence coding for a lipase involved in lipoprotein metabolism. The invention also concerns the preparation and use in therapy of said recombinant viruses, especially for the treatment or prevention of dyslipoproteinemia-related pathologies.10-15-2009
20100221225COMPOSITIONS AND METHODS FOR TREATING GLYCOGEN STORAGE DISEASES - Compositions and methods of use include therapeutically effective molecules for treatment of diseases in mammals including glycogen storage diseases (e.g., Pompe disease). These compositions in combination with various routes and methods of administration result in targeted uptake and expression of therapeutic molecules in specific organs, tissues and cells resulting in correction of a disease such as a glycogen storage disease (e.g., Pompe disease).09-02-2010
20080292593GENE THERAPY FOR SPINAL CORD DISORDERS - The disclosure pertains to methods and compositions for treating disorders affecting the central nervous system (CNS). These disorders include neurometabolic disorders such as lysosomal storage diseases that affect the central nervous system, e.g., Niemann-Pick A disease. They also include disorders such as Alzheimer's disease. The disclosed methods involve contacting an axonal ending of a neuron with a composition containing high titer AAV carrying a therapeutic transgene so that the AAV vector is axonally transported in a retrograde fashion and transgene product is expressed distally to the administration site.11-27-2008
20110110893THERAPEUTIC AGENT FOR ANAEROBIC DISEASES - The present invention provides a therapeutic agent for anaerobic diseases such as solid tumor, comprising in combination a pharmaceutical composition for the treatment of an anaerobic disease containing the transformed anaerobic microorganism as an active component and a pharmaceutical composition containing as an active component an anaerobic microorganism colonization and growth enhancer for enhancing the specific colonization and proliferation of the anaerobic microorganism at an anaerobic disease site. Furthermore, the present invention provides to an anaerobic microorganism colonization and growth enhancer for enhancing colonization and growth of the transformed anaerobic microorganism at a disease site that is in an anaerobic environment.05-12-2011
20110243895Generation of patient-specific differentiated cell types by epigenetic induction - Disclosure of a mammalian cytoplasmic donor cell line. Disclosure of a patient specific cell line. Methods to obtain a mammalian cytoplasmic donor cell line by fusing a differentiated mammalian cell and a functionally enucleated mammalian embryonic cell line. Methods to obtain a mammalian cytoplasmic donor cell line by fusing a differentiated mammalian cell and a functionally enucleated human cancer cell. Methods to obtain a patient specific cell line of a cell type similar to a mammalian cytoplasmic donor cell line by functionally enucleating the mammalian cytoplasmic donor cell line and fusing the functionally enucleated mammalian cytoplasmic donor cell line with a differentiated cell obtained from the patient. A method of treatment of a human patient by administering the patient-specific cell line to the patient.10-06-2011
20100303762Antifungal Polypeptides - Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include novel amino acid sequences, and variants and fragments thereof, for antipathogenic polypeptides that were isolated from microbial fermentation broths. Nucleic acid molecules comprising nucleotide sequences that encode the antipathogenic polypeptides of the invention are also provided. A method for inducing pathogen resistance in a plant using the nucleotide sequences disclosed herein is further provided. The method comprises introducing into a plant an expression cassette comprising a promoter operably linked to a nucleotide sequence that encodes an antipathogenic polypeptide of the invention. Compositions comprising an antipathogenic polypeptide or a transformed microorganism comprising a nucleic acid of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Transformed plants, plant cells, seeds, and microorganisms comprising a nucleotide sequence that encodes an antipathogenic polypeptide of the invention, or variant or fragment thereof, are also disclosed.12-02-2010
20090214476Novel mannose-specific adhesins and their use - The present invention relates to novel mannose-specific adhesins, and variants thereof, as well as nucleic acid sequences encoding these. The invention also relates to host cells expressing nucleic acids encoding the mannose-specific adhesins or variants thereof, as well as to pharmaceutical or nutraceutical compositions comprising the mannose-specific adhesins and/or host cells expressing the adhesins, and their use in treating or preventing bacterial infection. Further, screening methods suitable for identifying bacteria strains with probiotic properties are provided.08-27-2009
20110212060USE OF MICROPARTICLES CONTAINING GENETICALLY MODIFIED CELLS IN THE TREATMENT OF NEURODEGENERATIVE DISEASES - The present invention relates to methods for the treatment of neurodegenerative diseases by means of the use of microparticles comprising genetically modified cells expressing neurotrophic and/or angiogenic factors and wherein said microparticles are administered by means of implantation at the cerebral cortex level.09-01-2011
20110110892VECTORS FOR DELIVERING DISEASE NEUTRALIZING AGENTS - The invention relates in some aspects to recombinant herpes viruses and their use for expressing and delivering one or more disease-neutralizing agents to a subject to prevent or treat a disease in the subject. Some aspects of the invention relate to virus compositions and formulations comprising recombinant herpes viruses (e.g., recombinant gamma herpes viruses) that expresses one or more disease-neutralizing agents such as antibodies or other agents that can interfere with disease infection or progression. In some aspects, the invention relates to methods for preventing or treating an immunodeficiency virus associated disease. In some aspects, the invention relates to methods for preventing or treating AIDS.05-12-2011
20090035276USE OF A COMBINATION OF MYXOMA VIRUS AND RAPAMYCIN FOR THERAPEUTIC TREATMENT - The present invention relates to therapeutic use of a combination of Myxoma virus, including in combination with rapamycin. Treatment with rapamycin enhances the ability of Myxoma virus to selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon. The combination of rapamycin and Myxoma virus can be used to treat diseases characterized by the presence of such cells, including cancer. The invention also relates to therapeutic use of Myxoma virus that does not express functional M135R.02-05-2009
20110212058TARGETED MODULATION OF GENE EXPRESSION - The present invention relates to a method of modulating gene expression using snoRNA molecules or snoRNA like molecules or fragments, designed to target specific nucleic acid sequences.09-01-2011
20100239535METHOD FOR ISOLATING HOMOGENEOUS POPULATIONS OF TRANSDUCED PROGENITORS STABLY EXPRESSING SPECIFIC LEVELS OF A TRANSGENE - The invention is directed to a method for producing precursor cells expressing a target gene, for example VEGF, at desired levels comprising stably transducing precursor cells with the target gene linked to a cell-surface marker gene, for example truncated CD8/CD809-23-2010
20110212059PARAMYXOVIRUS VECTOR ENCODING ANGIOGENESIS GENE AND USE THEREOF - The present invention provides Paramyxovirus vectors encoding angiogenic genes and use of the same. The use of Paramyxovirus vectors enables effective transfer of angiogenic genes into individual tissues. FGF2 gene transferred into ischemic tissues in vivo induces expression of angiogenic genes without causing edema, and prevents necrosis due to ischemia. The vectors of the present invention are suitable for gene therapy targeted to ischemic tissues.09-01-2011
20100015095RESTORATION OF VISUAL RESPONSES BY IN VIVO DELIVERY OF RHODOPSIN NUCLEIC ACIDS - Nucleic acid vectors encoding light-gated cation-selective membrane channels, in particular channelrhodopsin-2 (Chop2), converted inner retinal neurons to photosensitive cells in photoreceptor-degenerated retina in an animal model. Such treatment restored visual perception and various aspects of vision. A method of restoring light sensitivity to a retina of a subject suffering from vision loss due to photoreceptor degeneration, as in retinitis pigmentosa or macular degeneration, is provided. The method comprises delivering to the subject by intravitreal or subretinal injection, the above nucleic acid vector which comprises an open reading frame encoding a rhodopsin, to which is operatively linked a promoter and transcriptional regulatory sequences, so that the nucleic acid is expressed in inner retinal neurons. These cells, normally light-insensitive, are converted to a light-sensitive state and transmit visual information to the brain, compensating for the loss, and leading to restoration of various visual capabilities.01-21-2010
20100034775RECOMBINANT ADENOVIRUS COMPRISING RECOMBINANT khp53 GENE AND THE PREPARATION METHOD AND USES THEREOF - A recombinant adenovirus vector comprises eukaryotic cell promoter, operator, Kozak sequence, exogenous gene and PolyA signal sequence from 5′ to 3′ in the adenovirus vector backbone. Optionally, introns are inserted between the operator and Kozak sequence, and the exogenous gene is p53 gene. A recombinant adenovirus obtained by co-transfection of the adenovirus vector and adenovirus backbone is also included in the invention. Also disclosed are the preparation methods and uses of the recombinant adenovirus vector and the recombinant adenovirus, respectively. The present invention further discloses a pharmaceutical composition for treating cancers, which comprises the recombinant adenovirus.02-11-2010
20100015096Fusion Proteins of Mycobacterium Tuberculosis - The present invention relates to compositions and fusion proteins containing at least two 01-21-2010
20090311219Oncolytic Adenoviruses for Cancer Treatment - The invention relates to an oncolytic adenovirus for the treatment of cancer, containing a human DNA sequence isolating a promoter conferring selective expression on an adenoviral gene. Said adenovirus can also contain a sequence that optimizes the protein translation of an adenoviral gene regulated by a promoter conferring tumor selectivity. The invention is suitable for use in the treatment of cancer.12-17-2009
20100034776REPLICATION-COMPETENT ANTI-CANCER VECTORS - Novel vectors which are replication competent in neoplastic cells and which overexpress an adenovirus death protein are disclosed. Some of the disclosed vectors are replication-restricted to neoplastic cells or to neoplastic alveolar type II cells. Compositions and methods for promoting the death of neoplastic cells using these replication-competent vectors are also disclosed.02-11-2010
20090035277Hepatitis C Virus Nucleic Acid Vaccine - The present invention features nucleic acid constructs that can be used as a HCV nucleic acid vaccine, vaccine component, or in the production of a HCV vaccine. Described constructs include those: (1) encoding for a chimeric HCV polypeptide containing a NS3-4A region based on a first HCV strain and an NS3-NS4A-NS4B-NS5A or an NS3-NS4A-NS4B-NS5A-NS5B region based on a second strain; and (2) a chimpanzee based adenovector encoding an HCV polypeptide.02-05-2009
20090035275Methods and formulations for protecting cells, and for treating diseases and conditions by optimizing the intracellular concentration of NAD - Pharmaceutical and cosmetic formulations and methods for optimizing the intracellular concentrations of NAD are provided. The present methods and compounds relate to the use of PBEF, PRPP and various forms of nicotinamide, individually or in combination, for therapeutic, cyto-protective, cosmetic and anti-aging purposes. PBEF, PRPP and nicotinamide, individually or in combination, as administered according to the invention, increase the metabolic fitness, health and performance of the cell, and thereby increase the cell's level of health during its lifecycle. By way of the present formulations and methods, optimizing the intracellular concentration of NAD02-05-2009
20110177032USE ON ONCOLYTIC HERPES VIRUSES FOR KILLING CANCER STEM CELLS - The invention, in some aspects, relates to the selective killing of cancer stem cells by oncolytic Herpes virus mediated oncolysis. In some aspects, the invention relates to methods for treating a subject having a cancer stem cell by administering to the subject an oncolytic Herpes virus. In other aspects, the invention provides methods for evaluating the efficacy of an oncolytic Herpes virus for killing cancer stem cells.07-21-2011
20110104117METABOLICALLY ACTIVATED RECOMBINANT VIRAL VECTORS AND METHODS FOR THEIR PREPARATION AND USE - Recombinant viral vectors, especially parvovirus vectors such as adeno-associated virus (AAV) vectors; capable of enhanced expression of heterologous sequences, and methods for their construction and use, are provided. The vectors have a structure, or are capable of rapidly adopting a structure, which involves intrastrand base pairing of at least one region in a heterologous sequence.05-05-2011
20110081318VIRAL COMPOSITIONS AND METHODS - Methods for producing recombinant viruses, compositions including the viruses, and uses for the compositions are described herein.04-07-2011
20110081317Enhancing Gene Transfer - Described herein are methods of improving the efficiency of gene transfer for a wide range of applications. Specifically provided are methods of increasing expression of an exogenous gene in a cell by contacting the cell with a vector comprising the exogenous gene and contacting the cell with a proteasome inhibitor, a lysosomal protease inhibitor and/or a microtubule inhibitor. Also provided are methods of delivering an antigen delivery vector to a cell or a subject. Provided are antigen delivery systems and kits comprising an antigen delivery vector and a proteasome inhibitor, a lysosomal protease and/or a microtuhulc inhibitor.04-07-2011
20110150840Detection and Treatment of Glyco-Enzyme-Related Disease - The present invention relates to the prevention and treatment of a disease, preferably brain cancer, by administration of an isolated DNA molecule comprising a gene encoding a protein having glycosyltransferase activity to a cell involved in the disease which is preferably a glioblastoma cell. A method of treating brain cancer is provided in which a tumor cell is transfected either ex vivo or in vivo with a composition comprising a DNA molecule that encodes a protein having glycosyltransferase activity resulting in inhibition of the growth or function of that cell.06-23-2011
20110150838LACTOBACILLUS PARACASEI STRAIN LT12 AS IMMUNITY REGULATORY AGENT - An isolated 06-23-2011
20100310515Latency Associated Protein Construct With Aggrecanase Sensitive Cleavage Site - The present provides a fusion protein comprising a latency associated peptide (LAP) and a pharmaceutically active agent in which the LAP and the pharmaceutically active agent are connected by an amino acid sequence comprising an aggrecanase proteolytic cleavage site.12-09-2010
20100310513BIFIDOBACTERIAL SPECIES - New bacterium GC61 belonging to the genus 12-09-2010
20100297084 METHOD FOR TRANSDUCING CELLS WITH PRIMARY CILIA - This invention provides methods for transducing a ciliated cell with a recombinant serotype 2 adeno-associated virus (AAV) vector. Additionally, the invention provides methods of treating diseases associated with a mutated gene by transducing a ciliated cell with a recombinant serotype 2 AAV vector containing a corrective transgene.11-25-2010
20120034188Akt Nucleic Acids, Polypeptides, and Uses Thereof - The present invention relates to human Akt3 proteins and polypeptides. The invention also relates to isolated nucleic acids encoding human Akt3, to vectors containing them and to their therapeutic uses, in particular for gene therapy. Expression of Akt3 inhibits cell death associated with hypoxia, apoptosis or necrosis.02-09-2012
20110150839METHOD TO OBTAIN TRANSGENIC PLANTS RESISTANT TO PHYTOPATHOGEN ATTACK BASED ON RNA INTERFERENCE (RNA) - The present invention relates to a method to obtain transgenic plants resistant to the attack of phytopathogens (i.e. parasites and phytophages) based on RNA interference, which contemplates the expression of double strand RNA (dsRNA) in the plant tissues, suitable for inhibiting the functionality of a GPCR receptor, whose functioning is vital for fungi, herbivorous insects or phytopathogenic nematodes.06-23-2011
20110150841Secretion System and Methods for its Use - The present invention provides reagents and methods for inhibiting bacterial infection and abnormal cell growth, as well as for selection cloning of nucleic acid inserts.06-23-2011
20090148408LACTOBACILLI EXPRESSING BIOLOGICALLY ACTIVE POLYPEPTIDES AND USES THEREOF - The present invention relates to 06-11-2009
20100003219Methods to Increase Transgene Expression From Bacterial-Based Delivery Systems by Co-Expressing Suppressors of the Eukaryotic Type I Interferon Response - Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene.01-07-2010
20090324546Method for modulating gene expression by modifying the cpg content - The invention relates to nucleic acid modifications for a directed expression modulation by the targeted insertion or removal of CpG dinucleotides. The invention also relates to modified nucleic acids and expression vectors.12-31-2009
20090324548Vaccinia Virus Strains - The invention provides attenuated vaccinia virus vaccines that can be used in methods to prevent or treat small pox in patients, as well as methods of obtaining such vaccines.12-31-2009
20090317362USE OF MYXOMA VIRUS FOR THE THERAPEUTIC TREATMENT OF CANCER AND CHRONIC VIRAL INFECTION - The present invention relates to therapeutic use of Myxoma virus. Myxomas virus can selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon and can be used to treat diseases characterized by the presence of such cells, including cancer.12-24-2009
20110177033RAS RESPONSIVE ELEMENT BINDING PROTEIN 1 (RREB1) AS A THERAPEUTIC TARGET FOR THALASSEMIAS AND SICKLE CELL ANEMIA - A method of screening compounds capable of activating ζ and/or ε globin gene promoter activity in an erythroid cell is disclosed. The methods comprises contacting in a medium a compound to be screened with RREB1; wherein the medium comprises a polynucleotide comprising the nucleotide sequence of 5′-M-C-M-C-A-M-M-H-M-M-M-3′, wherein M is the nucleotide adenine or cytosine, and H is the nucleotide adenine, cytosine or thymine; the RREB1 bindable to the polynucleotide; determining binding of the compound to the RREB1; and determining change in binding of the RREB1 to the polynucleotide; wherein detection of binding of the compound to the RREB1 and change in binding of the RREB1 to the polynucleotide is indicative that the compound is capable of activating ζ and/or ε globin gene promoter activity. Also disclosed is a method of activating ζ and/or ε globin gene promoter activity in an erythroid cell.07-21-2011
20100284971MODIFIED FACTOR VIII AND FACTOR IX GENES AND VECTORS FOR GENE THERAPY - The present invention relates to a modified and optimized Factor VIII or Factor IX nucleic acid for inclusion in a chimeric virus vector. Use of such vector can be used for treatment of hemophilia.11-11-2010
20080219953Cosmid dna constructs and methods of making and using same - Methods of inducing immune responses in individuals against a pathogen are disclosed. Methods of treating individuals susceptible to or suffering from a disease associated with a genetic defect which results in the non-production or under production of a protein or the production of a non-functioning or partially functioning protein are disclosed. Methods of delivering a protein to an individual are disclosed. Pharmaceutical compositions that comprise cosmids are disclosed.09-11-2008
20110165126Enhanced Submucosal Tissue Graft Constructs - An improved tissue graft construct comprising submucosa of a warm-blooded vertebrate and a preselected group of eukaryotic cells are described. The improved tissue graft constructs can be used in accordance with the present invention to enhance the repair of damaged or diseased tissues in vivo.07-07-2011
20110020282RECOMBINANT NEWCASTLE DISEASE VIRUS - The goal of the invention is to increase the therapeutical activity of oncolytic NDV. This issue is solved by a Newcastle Disease Virus comprising a recombinant nucleic acid, wherein the nucleic acid codes for a binding protein that has a therapeutic activity when expressed by the virus-infected tumor cell. Binding proteins belong to the following group: A natural ligand or a genetically modified ligand, a recombinant soluble domain of a natural receptor or a modified version of it, a peptide-ligand, an antibody molecule and derivatives thereof or antibody-like molecules like ankyrin repeat molecules or derivatives thereof.01-27-2011
20110256101SERCA2 THERAPEUTIC COMPOSITIONS AND METHODS OF USE - The present invention provides methods for treating pulmonary hypertension in a subject by delivering a therapeutic adeno-associated virus (AAV)-SERCA2 composition to a subject in need thereof.10-20-2011
20110135607VIRAL NUCLEIC ACID FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS - This invention relates to a non-coding RNA (ncRNA) sequence from Human cytomegalovirus (HCMV) (termed “TRL4”) that specifically protects neuronal cells from cell death and may therefore be useful in the treatment of neurodegenerative disorders, such as Parkinson's disease.06-09-2011
20110135606TEST SYSTEMS FOR THE ANALYSIS OF POLYPEPTIDES AND CELLS ADHERING TO SILICONES - The present invention relates in general to the field of diagnostics, namely to test systems for polypeptides in respect to silicone. More precisely, the present invention, in one embodiment thereof, concerns test systems for identifying and analyzing polypeptides adhering to silicone. Furthermore, the present invention relates to newly identified polypeptides adhering to silicone and to respective uses of such proteins, e.g., in test systems for detecting a response reaction of a mammal to a silicone.06-09-2011
20100166707EXTRACELLULAR MATRIX/METASTASIS MODIFIER GENES FOR THE PREVENTION OR INHIBITION OF METASTASIS OR GROWTH OF TUMOR AND FOR CHARACTERIZATION OF TUMOR - Disclosed are methods involving the administration of an extracellular matrix (ECM)/metastasis modifier gene, e.g., Anakin, Necdin, CentaurinD3 (CentD3), Csf1r, Brd4, Pi16, and Luc7l, for the prevention or inhibition of metastasis or of tumor growth. Further disclosed are methods of characterizing a tumor or cancer in a subject comprising detecting (i) a single nucleotide polymorphism (SNP) in an Anakin gene or a Brd4 gene of the subject, (ii) an amino acid substitution in an Anakin protein in the subject, or (iii) a level of expression of an Anakin gene or a Brd4 gene in the subject. Methods of screening a compound for anti-cancer activity and use of a compound with anti-cancer activity for the preparation of a medicament to treat or prevent cancer in a subject are also disclosed. Also disclosed is a method of inhibiting Sipa-1 in a subject.07-01-2010
20090175829Salmonella cancer therapeutics and related therapeutic methods - Therapeutic methods for treatment of solid tumor cancer cell masses, as can be effected using therapeutic compositions comprising 07-09-2009
20090175830ONCOLYTIC ADENOVIRUS ARMED WITH THERAPEUTIC GENES - The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway.07-09-2009
20090175827miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION - The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-16, using miR-16 to modulate a gene or gene pathway, using this profile in assessing the condition of a patient and/or treating the patient with an appropriate miRNA.07-09-2009
20090175826Genetically-engineered newcastle disease virus as an oncolytic agent, and methods of using same - Recombinant strains of avian paramyxovirus (APMV), such as Newcastle disease virus (NDV), are provided. Also provided are compositions comprising them, and methods of using them to lyse tumor cells and to treat cancer. In certain aspects, genetically-engineered viral strains that incorporate therapeutic transgenes are also provided. The recombinant viruses may be used in accordance with methods of providing enhanced oncolytic efficacy and delivering an oncolytic virus to tumors present in a patient. Also provided are methods for identifying a recombinant virus as an oncolytically-effective agent.07-09-2009
20100189691E. Coli Mediated Gene Silencing of Beta-Catenin - Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium or BTP. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating viral diseases and disorders. The bacterium or BTP includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells.07-29-2010
20120308522Therapeutic Use of Growth Factor, and Delivery Device, Especially for the Treatment of Intimal Hyperplasia - Vascular endothelial growth factor (VEGF) has utility in the treatment of intimal hyperplasia, hypertension and atherosclerosis, and of conditions susceptible to treatment with agents that produce nitric oxide or prostacyclin. Instead of VEGF, an equivalent agent such as an agonist of VEGF receptors may be given, as may nucleic acid encoding such an agonist. The agent may successfully be administered via the adventitial surface of a blood vessel, e.g. using a device which defines a reservoir between the body wall and the vessel's adventitial surface, the reservoir being at least part-filled by a pharmaceutical formulation containing the agent to be delivered.12-06-2012
20120308521Compositions and Methods for Treatment of Cancer Using Tissue-Specific Oncolytic Adenoviruses - The present invention includes the use of a nucleic acid sequence encoding an shRNA to target RNA interference against a cellular factor where such use can enhance oncolytic adenovius replication. The nucleic acid sequence encoding an shRNA can be introduced into an oncolytic adenovius construct via a recombination event, and such nucleic acid sequence encoding an shRNA can reside in either the E1 region or Fiber region of the oncolytic adenovius construct. In particular, the oncolytic adenovius construct optionally include a prostate specific promoter or prostate specific enhancer for issue specific expression in prostate cancer cells. The oncolytic adenovius constructs of the invention provides utility for the treatment of cancers, in particular prostate cancer.12-06-2012
20100247488Paramyxoviridae Virus Preparations - This document involves methods and materials related to obtaining Paramyxoviridae virus preparations.09-30-2010
20110104120Directed Evolution and In Vivo Panning of Virus Vectors - The present invention provides methods of achieving directed evolution of viruses by in vivo screening or “panning” to identify viruses comprising scrambled AAV capsids having characteristics of interest, e.g., tropism profile and/or neutralization profile (e.g., ability to evade neutralizing antibodies). The invention also provides scrambled AAV capsids and virus particles comprising the same.05-05-2011
20080305084Methods for delivering DNA to muscle cells using recombinant adeno-associated virus virions - The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.12-11-2008
20090068147RAAV VECTOR-BASED PRO-OPIOMELANOCORTIN COMPOSITIONS AND METHODS OF USE - Disclosed are methods for the use of pro-opiomelanocortin-encoding polynucleotides in the creation of transformed host cells and transgenic animals. In particular, the use of recombinant adeno-associated viral (rAAV) vector compositions, virions, and pluralities of virus particles that comprise a nucleic acid segment that expresses one or more mammalian pro-opiomelanocortin polypeptides in suitably transformed host cells is described. Also disclosed are methods for the treatment and amelioration of symptoms of a variety of conditions and disorders in an animal, including hyperinsulinemia, obesity, adiposity, overeating, and related eating disorders.03-12-2009
20110117058METHOD OF TREATING GENETIC DISORDERS - A method for the treatment of diseases associated with mutations in MYO7A or CEP290 genes, especially the Usher Syndrome type IB and Leber congenital amaurosis, by administering to a subject in need thereof an adeno-associated viral vector encoding a MYO7A or a CEP290 protein; genetic constructs and adeno-associated viral vectors for use in this method.05-19-2011
20090246176METHOD FOR TREATING DIABETES MELLITUS, OBESITY, CHRONIC FATIGUE, AGING, AND OTHER MEDICAL CONDITIONS BY UTILIZING MODIFIED VIRUS VIRIONS TO INSERT MESSENGER RIBONUCLEIC ACID MOLECULES INTO CELLS - The common link between diabetes mellitus, obesity, chronic fatigue and even aging may be related to deficiencies involving a body's metabolism of glucose and the ability to optimally conduct the necessary biologic processes of aerobic respiration. Utilizing a modified form of virus to deliver to cells in the body the messenger RNA molecules needed to construct insulin receptors and generate the enzymes that participate in the processes of glycolysis, the tricarboxylic acid cycle, oxidative phosphorylation and anaerobic respiration will lead to greater utilization of blood glucose and a more efficient and sustained production of the energy molecules that fuel the metabolic processes of the cell. Greater utilization of blood glucose will correct problems associated with diabetes, obesity, chronic fatigue, and aging.10-01-2009
20100226891SURFACE EXPRESSION VECTOR FOR FUSION PROTEIN OF MYO-2 PEPTIDE MULTIMER AND MYOSTATIN, AND MICROORGANISM TRANSFORMED BY THEREOF - The present invention relates to a fusion protein in which a myostatin mature protein is fused to a multimer of myostatin-derived antigenic peptide Myo-2, a surface expression vector containing a polynucleotide encoding the fusion protein, a recombinant microorganism transformed with the vector, and a feedstuff additive or a pharmaceutical composition containing the microorganism as an effective ingredient. The feedstuff additive or pharmaceutical composition according to the present invention can be used for muscle development and regulation of muscle growth in livestock and poultry, as well as for preventing and treating muscle-wasting diseases and degenerative diseases such as muscular dystrophy, muscular atrophy and the like. In addition, the transformed strain shows the same effect even if the strain itself after culture thereof is directly used, and thus it is very economical.09-09-2010
20090041724Protein Delivery System - The present invention relates to a virus-like particle (VLP) having a plasma membrane-derived lipid bilayer envelope, said VLP further comprising a viral structural protein, or fragment or derivative thereof, capable of forming an enveloped VLP, a fusiogenic protein and a recombinant target protein; methods for the delivery of recombinant target proteins to cells using said VLP, therapeutic methods using said VLP, compositions and kits comprising said VLP, methods of producing said VLP, and vectors and host cells for producing said VLP are also described.02-12-2009
20100158868Use of Fetal Cells for the Treatment of Genetic Diseases - The present invention provides iPS and stem cells derived from fetal somatic cells derived from a fetus in utero or from cord blood. The iPS and stem cells can be stored or used to treat genetic diseases.06-24-2010
20100272687MUTANT VIRUSES AND USES THEREOF - The present invention provides mutant viruses with a decreased ability to block nuclear transport of mRNA or protein in an infected cell which are attenuated in vivo. The mutant viruses of the present invention may also be capable of triggering the anti-viral systems of normal host cells while remaining sensitive to the effects of these systems. The present invention further provides for the use of the mutant viruses in a range of applications including, but not limited to, as therapeutics for the treatment of cancer and infections, as vaccines and adjuvants, as viral vectors, and as oncolytic and cytolytic agents for the selective lysis of malignant or infected cells.10-28-2010
20110305670NUCLEIC ACID ENCODING FUSION POLYPEPTIDES THAT PREVENT OR INHIBIT HIV INFECTION - The present invention is directed to an isolated nucleic acid molecule encoding a fusion polypeptide the expression of which in cells is capable of blocking the entry of HIV-1 into host cells and methods of using the nucleic acid molecule.12-15-2011
20080274084Anti-Tnf Alpha Producing Lactic Acid Bacteria for the Treatment of Chronic Enterocolitis - Treatments for chronic enterocolitis are disclosed. More specifically, methods for administration of pharmaceutical compositions that include anti-TNF-alpha antibody producing lactic acid microorganisms, such as 11-06-2008
20100310514Anti-Inflammatory Bacteria - Lactic acid bacteria expression cathelicidin, and methods of their use, are provided.12-09-2010
20090169514Expression Vectors Comprising the HS1 Promoter of the VAV1 Oncogene and Use Thereof for the Preparation of Pharmaceutical Compositions Intended for Somatic Gene Therapy - The present invention relates to the use of the HS1 promoter of the vav oncogene in the production of vectors selected from the groups of integrative vectors and non-integrative, non-plasmid vectors, for use in the preparation of pharmaceutical compositions intended for somatic gene therapy. By generating vectors that contain the HS1 promoter of the vav oncogene, it was possible to generate vectors in which the marker transgene or therapeutic transgene is expressed at moderate, but stable, levels in various cell lines both in vitro and in vivo.07-02-2009
20090047254Bacteriophage and their uses - There is provided a bacteriophage capable of lysing a 02-19-2009
20120148535ONCOLYTIC ADENOVIRUSES FOR TREATING CANCER - The invention is related to an oncolytic adenovirus that comprises a sequence encoding a hyaluronidase enzyme inserted in its genome. This adenovirus spreads more efficiently in the tumour mass and therefore the oncolytic effect is increased. Injecting the oncolytic adenovirus of the invention endovenously, tumour volume regressions are obtained. Therefore the oncolytic adenovirus of the present invention is useful for the treatment of a cancer or a pre-malignant state of cancer.06-14-2012
20100310517GROWTH FACTOR MEDIATED COSMECEUTICALS AND USE THEREOF TO ENHANCE SKIN QUALITY - It has been discovered that vascular endothelial growth factor (“VEGF”) promotes migration of activated (but not differentiating) keratinocytes to skin. This growth factor specifically increases migration of keratinocytes of the “wounded skin” phenotype but does not have significant effects upon differentiated keratinocytes. It also increases collagen deposition and reduces wrinkles, enhances skin quality, and increases skin thickness to normal levels in individuals where skin has thinned due to age or disorder such as diabetes. It is particularly well suited for use as cosmeceuticals when applied in purified form and in known amounts. The data presented in the examples demonstrate efficacy and specificity of VEGF in enhancing migration of normal human keratinocytes as well as formation of new granulation tissue including collagen formation. VEGF induces keratinocyte and fibroblast migration, formation of new tissue, and not only induces deposition of collagen but improves alignment of the collagen fibers. Accordingly, this growth factor is highly suitable for use as a cosmeceutical, especially for skin resurfacing and reduction in wrinkles.12-09-2010
20080219954Method for rapid screening of bacterial transformants and novel simian adenovirus proteins - Chimpanzee serotype C68 proteins, peptides, and polypeptide are provided. Also provided are novel adenoviruses derived from these proteins, as well as compositions containing these proteins and methods of using same for immunization and therapy. Further, a rapid method for screening recombinant transformants using a visually detectable method is described.09-11-2008
20120156169RECOMBINANT MYCOBACTERIUM STRAIN EXPRESSING A MYCOBACTERIAL FAP PROTEIN UNDER THE CONTROL OF A PROMOTER ACTIVE UNDER HYPOXIA AND ITS APPLICATION FOR CANCER THERAPY - The invention relates to a recombinant vector comprising a mycobacterial FAP protein coding sequence under the transcriptional control of a promoter active under hypoxia conditions and its use for the prevention and the treatment of epithelial tumors.06-21-2012
20090028825Compositions and Methods for Studying and Treating Inflammatory Diseases and Disorders - Disclosed are compositions and methods that can be used in the treatment of diseases and disorders caused, exacerbated or otherwise affected by inflammation.01-29-2009
20110318308LIPOCALIN-TYPE PROSTAGLANDIN D2 SYNTHASE AS A BIOMARKER FOR LUNG CANCER PROGRESSION AND PROGNOSIS - A PGD(2) receptor (DP) deficiency enhances tumor progression accompanied by abnormal vascular expansion. In tumors, angiogenic endothelial cells highly express DP receptor, and its deficiency accelerates vascular leakage and angiogenesis. Administration of a synthetic DP agonist, BW245C, markedly suppresses tumor growth as well as tumor hyperpermeability in WT mice, but not in DP-deficient mice. In a corneal angiogenesis assay and a modified Miles assay, host DP deficiency potentiates angiogenesis and vascular hyperpermeability under COX-2-active situation, whereas exogenous administration of BW245C strongly inhibits both angiogenic properties in WT mice. In an in vitro assay, BW245C does not affect endothelial migration and tube formation, processes that are necessary for angiogenesis; however, it strongly improves endothelial barrier function via an increase in intracellular cAMP production. PGD(2)/DP receptor is a newly identified regulator of tumor vascular permeability, indicating DP agonism can be exploited as a therapy for the treatment of cancer.12-29-2011
20110318307XIAP THERAPY - The invention features methods, compositions and kits for the treatment of retinal degenerative disorders.12-29-2011
20100003218HYBRID-AAV VECTORS TO DELIVER LARGE GENE EXPRESSION CASSETTE - Hybrid adeno-associated virus (AAV) vector systems able to efficiently express therapeutic target genes larger than may be carried in a single AAV vector are provided, wherein a highly recombinogenic foreign DNA sequence is incorporated into two or more ITR-mediated AAV vectors. In one aspect of one embodiment, the novel hybrid AAV vector system is a hybrid dual AAV (hdAAV) vector system. In another aspect of one embodiment, the novel hybrid AAV vector system is a hybrid tri AAV (htAAV) vector system. A method of treating a clinical disease caused at least in part by a defective gene is provided, and comprises (1) providing a hybrid AAV vector system capable of expressing a therapeutic target gene, wherein the therapeutic target gene is capable of replacing, restoring or counteracting the effects of the defective gene; and (2) administering a therapeutic amount of said vector system to a subject wherein said therapeutic target gene is expressed at levels having a therapeutic effect.01-07-2010
20120301434ANTIBACTERIAL POLYPEPTIDES AND USE THEREOF - The present invention discloses polypeptides with antibacterial properties and use said polypeptides and/or polynucleotides encoding said polypeptides in the preparation of medicament for the treatment of infectious diseases. The inventors also provide vectors encoding and adapted for expression of the polypeptides and polynucleotides of the invention. The vectors may be used in the preparation of a medicament for the treatment of bacterial infections. Further, the vector of the invention may be used to reduce the load of bacteria in food and/or feed.11-29-2012
20120301433BACTERIOPHAGES EXPRESSING AMYLOID PEPTIDES AND USES THEREOF - The present invention generally relates to engineered bacteriophages which express amyloid peptides for the modulation (e.g. increase or decrease) of protein aggregates and amyloid formation. In some embodiments, the engineered bacteriophages express anti-amyloid peptides for inhibiting protein aggregation and amyloid formation, which can be useful in the treatment and prevention of and bacterial infections and biofilms. In some embodiments, the engineered bacteriophages express amyloid peptides for promoting amyloid formation, which are useful for increasing amyloid formation such as promoting bacterial biofilms. Other aspects relate to methods to inhibit bacteria biofilms, and methods for the treatment of amyloid related disorders, e.g., Alzheimer's disease using an anti-amyloid peptide engineered bacteriophages. Other aspects of the invention relate to engineered bacteriophages to express the amyloid peptides on the bacteriophage surface and/or secrete the amyloid peptides, e.g., anti-amyloid peptides and pro-amyloid peptides, and uses thereof for modulation protein aggregates and amyloid formation.11-29-2012
20100310516Duplexed Parvovirus Vectors - The present invention provides duplexed parvovirus vector genomes that are capable under appropriate conditions of forming a double-stranded molecule by intrastrand base-pairing. Also provided are duplexed parvovirus particles comprising the vector genome. Further disclosed are templates and methods for producing the duplexed vector genomes and duplexed parvovirus particles of the invention. Methods of administering these reagents to a cell or subject are also described. Preferably, the parvovirus capsid is an AAV capsid. It is further preferred that the vector genome comprises AAV terminal repeat sequences.12-09-2010
20120009153COMPOSITIONS FOR BACTERIAL MEDIATED GENE SILENCING AND METHODS OF USING THE SAME - The invention features compositions and methods for delivering small interfering (siRNAs), e.g., shRNAs, to host cells using non-pathogenic strains of 01-12-2012
20090053178USE OF HERPES VECTORS FOR TUMOR THERAPY - Eliciting a systemic antitumor immune response, in a patient who presents with or who is at risk of developing multiple metastatic tumors of a given cell type, entails, in one embodiment, inoculating a tumor in the patient with a pharmaceutical composition consisting essentially of (A) a herpes simplex virus (HSV) that infects tumor cells but that does not spread in normal cells and (B) a pharmaceutically acceptable vehicle for the virus, such that an immune response is induced that is specific for the tumor cell type and that kills cells of the inoculated tumor and of a non-inoculated tumor. In another embodiment, the pharmaceutical composition also comprises a defective HSV vector which contains an expressible nucleotide sequence encoding at least one immune modulator. In another embodiment, the pharmaceutical composition contains a second HSV that infects tumor cells but that does not spread in normal cells. According to the latter approach, both the first HSV and the second HSV may have genomes that comprise, respectively, an expressible nucleotide sequence coding for at least one immune modulator. In another embodiment, the pharmaceutical composition comprises, in addition to a herpes simplex virus (HSV) that infects tumor cells but that does not spread in normal cells, a viral vector comprising at least one expressible nucleotide sequence coding for at least one immune modulator.02-26-2009
20120014922INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA - The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives.01-19-2012
20100183559BIFIDOBACTERIUM LONGUM - The multiple embodiments described herein comprise the genome of a probiotic 07-22-2010
20120014920ANNEXIN AND ITS USE TO TREAT INFLAMMATORY DISORDERS - There is provided a composition comprising an effective amount of Annexin A01-19-2012
20120058086COMPOSITIONS, KITS, AND METHODS FOR PROMOTING ISCHEMIC AND DIABETIC WOUND HEALING - Compositions, kits and methods for promoting diabetic wound healing are based on the discovery that SDF-1α specifically upregulates expression of E-selectin in mature endothelial cells (EC), leading to an increase in EC-endothelial progenitor cell (EPC) adhesion and EPC homing. Methods for promoting healing of a wound in a diabetic subject include providing a therapeutically effective amount of a composition including E-selectin protein or a nucleic acid encoding E-selectin protein, and optionally, an agent that specifically upregulates E-selectin expression (e.g., SDF-1α). The methods can also include administering hyperbaric oxygen treatment to the subject. Administering the composition to the subject results in migration of bone marrow-derived progenitor cells to the wound, accelerated wound healing, and upregulation of E-selectin expression in the subject.03-08-2012
20120114607SAFE LENTIVIRAL VECTORS FOR TARGETED DELIVERY OF MULTIPLE THERAPEUTIC MOLECULES - The present application discloses a lentiviral transfer system which includes: (i) a self-inactivating transfer vector comprising: multiple gene units, wherein each gene unit includes a heterologous nucleic acid sequence operably linked to a regulatory nucleic acid sequence; and (ii) a helper construct which lacks a 5′ LTR, wherein the 5′ LTR has been replaced with a heterologous promoter, in which the helper construct further comprises: a lentiviral env nucleic acid sequence containing a deletion, wherein the deleted env nucleic acid sequence does not produce functional env protein; and a packaging signal contains a deletion, wherein the deleted packaging signal is nonfunctional.05-10-2012
20100034774Serotype of adenovirus and uses thereof - Adenovirus serotypes differ in their natural tropism. The adenovirus serotypes 2, 4, 5 and 7 all have a natural affiliation towards lung epithelia and other respiratory tissues. In contrast, serotypes 40 and 41 have a natural affiliation towards the gastrointestinal tract. The serotypes described differ in at least capsid proteins (penton-base, hexon), proteins responsible for cell binding (fiber protein), and proteins involved in adenovirus replication. This difference in tropism and capsid protein among serotypes has led to the many research efforts aimed at redirecting the adenovirus tropism by modification of the capsid proteins.02-11-2010
20120156170DRUG COMPOSITION FOR ANGIOGENESIS THERAPY - The present invention relates to: drug compositions of angiogenesis therapy that contains gene coding for human prostacyclin synthase (hPGIS) synthesizing prostaglandin I06-21-2012
20120156168VIRUSES FOR THE TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS - Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately directly contacts proliferating cells having an activated Ras-pathway. Proliferative disorders include but are not limited to neoplasms. The virus is selected from modified adenovirus, modified HSV, modified vaccinia virus and modified parapoxvirus orf virus. Also disclosed are methods for treating cell proliferative disorders by further administering an immunosuppressive agent.06-21-2012
20120156167ENHANCIN GENE BEL1 FROM BACILLUS THURINGIENSIS AND ITS USE IN BIOLOGICAL INSECTICIDE - The isolation, cloning of an enhancin gene bel1 from 06-21-2012
20120207711INFECTIVITY-ENHANCED CONDITIONALLY-REPLICATIVE ADENOVIRUS AND USES THEREOF - A modified adenovirus capable of overcoming the problem of low level of coxsackie-adenovirus receptor (CAR) expression on tumor cells and methods of using such adenovirus are provided. The fiber protein of the adenovirus is modified by insertion or replacement so as to target the adenovirus to tumor cells, and the replication of the modified adenovirus is limited to tumor cells due to specific promoter control or mutations in E1a or E1b genes.08-16-2012
20100189690PSEUDOTYPING OF RETROVIRAL VECTORS, METHODS FOR PRODUCTION AND USE THEREOF FOR TARGETED GENE TRANSFER AND HIGH THROUGHPUT SCREENING - The invention relates to the pseudotyping of retroviral vectors with heterologous envelope proteins derived from the Paramyxoviridae family, genus 07-29-2010
20100143303COMPOSITION COMPRISING LACTIC ACID BACTERIUM HAVING HIGH ANTI-ALLERGIC ACTIVITY, AND METHOD FOR PRODUCTION OF THE LACTIC ACID BACTERIUM - It is to provide a lactic acid bacterium having a high antiallergic activity and stable antiallergic activity that can be used effectively in various product forms and in various use applications. By conducting a heat treatment at 60 C. or more and less than 100° C. for 10 minutes or more and less than 60 minutes to 06-10-2010
20100291037IMMUNOGENICITY USING A COMBINATION OF DNA AND VACCINIA VIRUS VECTOR VACCINES - This invention relates to improved methods of inducing an immune response for the prevention or treatment of HIV-1 infection by using a nucleic acid vaccine in conjunction with a recombinant viral vaccine, e.g., a poxvirus vaccine, to potentiate and broaden the immune response. The present invention further provides a particularly effective vaccine regimen comprising a DNA vaccine used in combination with a poxvirus virus, especially NYVAC or ALVAC.11-18-2010
20110104121Female Reproductive Tract and Anal Prophylaxes - The present invention provides methods for boosting mucosal immunity in the female reproductive tract of pre- and post-menopausal women using a TGF-beta inhibitor, a Selective Estrogen Receptor Modulator, and/or a recombinant commensal bacterium that expresses endogenous microbicides into the intestinal tract or reproductive tract of a subject. It also provides methods for boosting innate and adaptive immunity by providing a glucocorticoid. Methods for preventing sexually transmitted infections including HIV infection are also provided.05-05-2011
20110104118COMPOSITIONS AND METHODS FOR THERAPEUTIC USE - A method and pharmaceutical composition for the treatment of cancer using a gene delivery system, such as a viral vector delivery system, comprising a therapeutic gene such as p53 or a retinoblastoma tumor suppressor gene wherein the gene delivery system is formulated in a buffer comprising a delivery-enhancing agent such as ethanol or a detergent.05-05-2011
20110104119Chimeric Vectors - The present invention is based, in part, on the discovery that parvovirus (including AAV) capsids can be engineered to incorporate small, selective regions from other parvoviruses that confer desirable properties. The inventors have discovered that in some cases as little as a single amino acid insertion or substitution from a first parvovirus (e.g., an AAV) into the capsid structure of another parvovirus (e.g., an AAV) to create a chimeric parvovirus is sufficient to confer one or more of the desirable properties of the first parvovirus to the resulting chimeric parvovirus and/or to confer a property that is not exhibited by the first parvovirus or is present to a lesser extent.05-05-2011
20120251499METHOD FOR DIAGNOSIS/PROGNOSIS OF CANCERS USING AN EPIGENETIC MARKER CONSISTING OF A SPECIFIC SINGLE CPG SITE IN TTP PROMOTER AND TREATMENT OF CANCERS BY REGULATING ITS EPIGENETIC STATUS - The present invention relates to a method for the diagnosis and prognosis of cancers using an epigenetic marker consisting of a specific single CpG site in TTP (Tristetraprolin) promoter and treatment of cancers by regulating its epigenetic status. Particularly, the present invention relates to a method for the diagnosis and prognosis of liver cancer by measuring specific methylation of C, the 3210-04-2012
20120251498Gene Delivery to Organs - Application of a virus with poloxamer alone onto atria results in diffuse epicardial gene transfer with negligible penetration into the myocardium. Progressive increases in protease concentration, however, allow transmural gene transfer. After protease exposure, echocardiographic left atrial diameter does not change. Left atrial ejection fraction decreases on post-operative day 3, but returns to baseline by day 7. At appropriate protease concentrations, tissue tensile strength is unaffected by the procedure. Transmural atrial gene transfer can be effected using this direct “painting” method.10-04-2012
20100129322TETRACYCLINE-SENSITIVE BIFIDOBACTERIA STRAINS - Many probiotic Bifidobacteriacea contains an active tetW that renders the cells resistant to tetracycline. This presents a theoretical risk of a horizontal transfer of functional antibiotic genes. The present invention relates to novel tetracycline-sensitive strains of the well-known probiotic 05-27-2010
20100092428Method For Using A Bacillus Subtilis Strain To Enhance Animal Health - The present invention relates to a method for enhancing the health of an animal comprising administering to the animal a composition comprising 04-15-2010
20120121543ANTI-MICROBIAL AGENT FROM PAENIBACILLUS SP. AND METHODS AND USES THEREOF - The present invention provides, in part, a 05-17-2012
20120164106ADENO-ASSOCIATED VIRUS VIRIONS WITH VARIANT CAPSID AND METHODS OF USE THEREOF - The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.06-28-2012
20100247487IN VIVO AND EX VIVO GENE TRANSFER INTO RENAL TISSUE USING GUTLESS ADENOVIRUS VECTORS - A method for treating a renal disease in a subject is disclosed. The method includes administering into a kidney of the subject with an effective amount of a gutless adenoviral vector containing a polynucleotide encoding a therapeutic agent. The gutless adenoviral vector contains the nucleotide sequence of SEQ ID NO:13 or SEQ ID NO:15 and expresses the therapeutic agent in a kidney tissue of the subject.09-30-2010
20100247486Recombinant virus vector originating in HHV-6 or HHV-7, method of producing the same, method of transforming host cell using the same, host cell transformed thereby and gene therapy method using the same - It is intended to provide a virus vector by which an exogenous nucleotide sequence can be inserted and easily transferred into a mammalian host cell and a gene encoded by the exogenous nucleotide sequence can be expressed in the host cell, and which has a low risk of pathogenicity and is appropriately usable in gene therapy of mammals. Namely, a recombinant vector originating in HHV-6 which has an exogenous nucleotide sequence in a portion corresponding to at least one region selected from the group consisting of U2, U3, U4, U5, U6, U7, U8, U24, and U25 regions of HHV-6; or a recombinant vector originating in HHV-7 which has an exogenous nucleotide sequence in a portion corresponding to at least one region selected from the group consisting of U2, U3, U4, U7, U8, U24, U24a, and U25 regions of HHV-7.09-30-2010
20080286237Systemic Treatment of Metastatic and/or Systemically-Disseminated Cancers using GM-CSF-Expressing Poxviruses - The present invention concerns methods and compositions for the treatment of cancer and cancer cells using intravascular administration of a vaccinia virus. In some embodiments, methods and compositions involve a replicative vaccinia virus that encodes GM-CSF.11-20-2008
20120128631COMPOSITIONS AND METHODS FOR KINASE-MEDIATED CYTOPROTECTION AND ENHANCED CELLULAR ENGRAFTMENT AND PERSISTENCE - Disclosed are methods of protecting cells, especially non-vascular system, non-hematopoietic cells and tissues, from apoptosis and enhancing their engraftment, survival, and/or persistence by providing enhanced levels of PIM activity for the cell, including PIM-1 activity. Also disclosed are cells that have been engineered to express enhanced levels of PIM kinase, and methods of administering those cells to vertebrates.05-24-2012
20100209392Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith - Stable pharmaceutical compositions comprising recombinant adeno-associated virus (AAV) virions are described. The compositions provide protection against loss of recombinant AAV vector genomes and transduceability under conditions such as exposure to cycles of freezing and thawing and storage in glass or polypropylene vials. The compositions comprise recombinant AAV virions in combination with one or more dihydric or polyhydric alcohols, and, optionally, a detergent, such as a sorbitan ester. Also described are methods of using the compositions.08-19-2010
20110182859Compositions and methods for therapeutic delivery with microorganisms - Certain embodiments disclosed relate to compositions, including therapeutic compositions, methods, devices, and systems that include modified microorganisms including at least one genetic element encoding at least one therapeutic agent or environmental treatment agent.07-28-2011
20100068183Methods of treating lysosomal storage related diseases by gene therapy - Isolated nucleic acid-based vectors and lentivirus vectors, and methods of using those vectors to inhibit or prevent metabolic disorders in a mammal, are provided.03-18-2010
20120315248COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ATTENUATED ONCOLYTIC VIRUSES - Compositions including attenuated oncolytic viruses and methods of their use for the treatment of cancer are disclosed. Some attenuated virus exhibit potential as tumor therapies by exhibiting characteristics such as high selectivity, infectivity, cytotoxicity, or replication index for tumor cells, and/or low infectivity, cytotoxicity, or replication index for normal cells. In preferred embodiments, the ratio of replication of virus in normal cells:tumor cells is about 1:100 or greater. Preferred viruses have two or more mechanisms of attenuation including insertion of a transgene such as GFP or an interferon, preferably at position 1 of the viral genome. The compositions can be administered to subjects having tumors, in an effective amount to delay or inhibit the growth of a tumor, reduce the growth or size of the tumor, and/or inhibit or reduce metastasis of the tumor. Methods for manufacturing viruses and methods of testing their oncolytic potential are also disclosed.12-13-2012
20120213738Cardiac Repair By Reprogramming of Cardiac Fibroblasts Into Cardiomyocytes - The present invention involves the use of transcription factors including Tbx5, Mef2C, Hand2, myocardin and Gata4 to reprogram cardiac fibroblasts into cardiomyocytes, both in vitro and in vivo. Such methods find particular use in the treatment of patients post-myocardial infarction to prevent or limit scarring and to promote myocardial repair.08-23-2012
20120213736PARVOVIRUS METHODS AND COMPOSITIONS FOR KILLING NEOPLASTIC CELLS - According to the invention, parvoviruses such as the adeno-associated virus Type 2 (AAV2) are found to be oncolytic, selectively mediating apoptosis in cancer cells and their precursors, while leaving healthy cells intact. The invention also includes a method of killing cancer and other neoplastic and preneoplastic cells by administrating to said cells the AAV2 proteins Rep78 or Rep 68, expression constucts encoding the same, or pharmaceutical compositions comprising the same.08-23-2012
20100172872Treatment of Cancer Using HSV Mutant - Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the γ34.5 gene in the long repeat region (R07-08-2010
20120171159NON-PATHOGENIC AND/OR ATTENUATED BACTERIA CAPABLE OF INDUCING APOPTOSIS IN MACROPHAGES, PROCESS OF MANUFACTURING AND USES THEREOF - The invention relates to an non-pathogenic and/or attenuated bacterium which is capable of inducing apoptosis in macrophages.07-05-2012
20120171160EXPRESSION OF VIRUS ENTRY INHIBITORS AND RECOMBINANT AAV THEREFOR - The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver genes encoding human immunodeficiency virus entry inhibitors to target cells in mammals.07-05-2012
20100254945Rnai Therapeutic for Respiratory Virus Infection - Disclosed herein is a double stranded siRNA molecule that inhibits production of a respiratory virus, wherein each strand of said siRNA molecule is about 15 to about 50 nucleotides, and wherein one strand of said siRNA molecule comprises a nucleic acid sequence identical to a conserved site, or a variant thereof, within the nucleic acid sequence of the respiratory virus, and uses thereof.10-07-2010
20100047208Construction of oncolytic adenovirus recombinant specifically expressing immune modulatory factor gm-csf in tumor cells and uses thereof - The present invention relates to gene therapy for tumors, specifically, it relates to the construction of oncolytic adenovirus recombinant, which specifically expresses immune modulatory factor GM-CSF in tumor cells and uses thereof.02-25-2010
20120177605Delivery of Polynucleotides Across the Blood-Brain-Barrier Using Recombinant AAV9 - The present invention relates to methods and materials useful for systemically delivering polynucleotides to the spinal cord. Use of the methods and materials is indicated, for example, for treatment of lower motor neuron diseases such as spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) as well as Pompe disease and lysosomal storage disorders.07-12-2012
20100272686ONCOLYTIC VIRUS - Malignant tumors that are intrinsically resistant to conventional therapies are significant therapeutic challenges. An embodiment of the present invention provides an oncolytic virus capable of killing target cells, such as a tumor cells. In various embodiments presented herein, the oncolytic virus is armed or encodes a therapeutic polypeptide. In at least one embodiment, a recombinant oncolytic virus has been generated that can specifically replicate in cancer cells leading to their destruction and at the same time secrete robust amounts of a therapeutic polypeptide. Compositions and methods disclosed herein have broad therapeutic applicability.10-28-2010
20100272685Porcine Adeno-Associated Viruses - Porcine tissues were screened for the presence of Adeno-Associated Viruses (AAV). Several AAV sequences were isolated from various porcine tissues, and BLAST analysis confirmed high to low homology with known AAV sequences of different origin. Sequence analysis confirmed the isolation of at least three novel porcine AAV isolates which we named AAVpo1, -po2, and -po3. Novel AAVs derived from porcine tissues may significantly contribute to the generation of new preventive or curative clinical modalities acceptable for human use.10-28-2010
20100272684HYPERBARIC TREATMENT IN WOUND HEALING - This invention relates to methods for treating chronic dermal ulcers using hyperbaric treatment in combination with progenitor cells and chemokine homing factors. Specifically, the invention relates to treatment of chronic wounds resulting from diabetes mellitus using compositions comprising EPC and SDF-1A, under hyperbaric condition to accelerate wound healing.10-28-2010
20100028302Use of IGFBP-2 in Senescence Diseases and for the Maintenance of Organ Functions - The present invention relates to the use of an IGFBP-2 (insulin-like growth factor binding protein-2) molecule for the production of a pharmaceutical composition for the regulation of senescence processes in cells, tissues and/or organs for the maintenance and control of tissue and/or organ functions and/or for the treatment or alleviation of senescence symptoms or early senescence, wherein the IGFBP-2 molecule is selected from the group of an IGFBP-2 polypeptide or of a functional fragment thereof and of a nucleic acid encoding an IGFBP-2 polypeptide or a functional fragment or derivative thereof. Moreover, corresponding methods of treatment are provided. The use of IGFBP-2 in the preparation of a pharmaceutical composition in the medical intervention of cachexia is described.02-04-2010
20100266545OBLIGATELY ANAEROBIC MUTANT LACTIC ACID BACTERIUM AND PREPARATION METHOD THEREFOR, AND EXPRESSION VECTOR FUNCTIONING IN OBLIGATELY ANAEROBIC LACTIC ACID BACTERIUM - The present invention provides an obligately anaerobic lactic acid bacterium having no risk of causing side effects in normal tissue and promising as a safe therapeutic agent and a gene transporter for a disease that is in an anaerobic environment such as a solid tumor, a preparation method therefor, and an expression vector useful in the preparation method. The obligately anaerobic lactic acid bacterium of the present invention has been artificially mutated from being facultatively anaerobic to being obligately anaerobic and, furthermore, is capable of being transformed by an expression vector having introduced thereinto a gene for expressing an active protein useful for the treatment of a disease that is in an anaerobic environment. Furthermore, the expression vector of the present invention functions in an obligately anaerobic lactic acid bacterium and contains a 10-21-2010
20100239536Modified Bacteriophage Including an Alpha/Beta Small Acid-Soluble Spore Protein (SASP) Gene - Provided is a modified bacteriophage capable of infecting a target bacterium, which bacteriophage includes an α/β small acid-soluble spore protein (SASP) gene encoding a SASP which is toxic to the target bacterium, wherein the SASP gene is under the control of a constitutive promoter which is foreign to the bacteriophage and the SASP gene.09-23-2010
20100297083Polynucleotides and Polypeptide of Human KV1.3, Compositions Comprising Same and Methods of Using Same - An isolated polypeptide comprising, contiguously, a first amino acid sequence being at least 90% homologous to amino acid coordinates 1-398 of SEQ ID NO: 2, a tryptophan residue and a second amino acid sequence being at least 90% homologous to amino acid coordinates 400-523 of SEQ ID NO: 2. Also provided are polynucleotide sequences encoding this polypeptide and uses of same in the treatment of medical conditions associated with ion channel insufficiency.11-25-2010
20120189582SIMIAN ADENOVIRUS 41 AND USES THEREOF - Novel simian adenovirus 41 and two isolates thereof are described. Various uses of these isolates, including construction of a recombinant vector which comprises simian adenovirus 41 sequences and a heterologous gene under the control of regulatory sequences are provided. A cell line which expresses simian adenovirus 41 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.07-26-2012
20120082648Colonization factor (CF) antigens of enterotoxigenic escherichia coli in recombinant bacteria - strains, such as enterotoxigenic 04-05-2012
20090169512VACCINIA VIRUS STRAINS - The invention provides attenuated vaccinia virus vaccines that can be used in methods to prevent or treat small pox in patients, as well as methods of obtaining such vaccines.07-02-2009
20090016992PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells.01-15-2009
20120230954Drug Comprising As The Active Ingredient Proliferative Vector Containing Survivin Promoter - It is intended to provide a drug to be used in gene therapy which specifically targets abnormal cells such as tumor cells and destroys the same for healing. Namely, a drug comprising, as the active ingredient, a proliferative vector which contains a Survivin promoter proliferating depending on the expression of Survivin. The drug may be used in order to treat tumor. In this drug, use may be made of an adenovirus as the vector. In the adenovirus of this drug, an endogenous promoter of an E1A domain may be substituted with a Survivin promoter.09-13-2012
20080299082Novel recombinant T4 phage particle containing HIV, H. pylori or cancer antigens and uses thereof - The invention is directed to a novel recombinant T4 phage particle expressing a HOC and/or SOC 12-04-2008
20080299084BACTERIALLY DERIVED INTACT MINICELLS THAT ENCOMPASS PLASMA FREE FUNCTIONAL NUCLEIC ACID FOR IN VIVO DELIVERY TO MAMMALIAN CELLS - Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.12-04-2008
20110002890Treatment of tumors with genetically engineered herpes virus - Disclosed are methods for treating cancer by administering an effective amount of a modified Herpes simplex virus.01-06-2011
20110002889Cultures with Improved Phage Resistance - The present invention provides methods and compositions related to modulating the resistance of a cell against a target nucleic acid or a transcription product thereof. In some preferred embodiments, the present invention provides compositions and methods for the use of one or more cas genes or proteins for modulating the resistance of a cell against a target nucleic acid or a transcription product thereof. In some embodiments, the present invention provides methods and compositions that find use in the development and use of strain combinations and starter culture rotations. In additional embodiments, the present invention provides methods for labelling and/or identifying bacteria. In some preferred embodiments, the present invention provides methods for the use of CRISPR loci to determine the potential virulence of a phage against a cell and the use of CRISPR-cas to modulate the genetic sequence of a phage for increased virulence level. In still further embodiments, the present invention provides means and compositions for the development and use of phages as biocontrol agents.01-06-2011
20110044949ONCOLYTIC VIRUS REPLICATING SELECTIVELY IN TUMOR CELLS - By using a virus having a gene sequence comprising a telomerase promoter and an E1 gene (preferably a sequence comprising E1A gene, IRES sequence and E1B gene) or by using an anticancer agent comprising the virus, the virus replicates in cancer cells to thereby produce an efficient anticancer effect.02-24-2011
20110044948POXVIRAL ONCOLYTIC VECTORS - A poxvirus comprising a defective F2L gene and compositions comprising such poxvirus are useful for therapeutic purposes, and more particularly for the treatment of cancer.02-24-2011
20110044947METHODS OF TREATING CARDIAC DISORDERS - The invention feature methods and compositions for treating ischemic and reperfusuin related injury such as cardiac disorders.02-24-2011
20120269773RECOMBINANT ADENOVIRUSES ENCODING THE SPECIFIC IODINE TRANSPORTER (NIS) - The present invention relates to the field of gene therapy and the treatment of tumors.10-25-2012
20090180989Compositions and methods for delivering nucleotide sequences to vertebrates - The invention includes methods of producing viral particles which include introducing into avian cells a nucleotide sequence encoding a replication deficient retroviral vector and introducing into the avian cells nucleotide sequence encoding products required for replication of the replication deficient retroviral vector, harvesting the viral particles and can include administering the viral particles to vertebrate cells.07-16-2009
20100233126POLYPEPTIDE - The present invention provides 5T4 tumour-associated antigen (TAA) for use in a method of immunotherapy of tumours. The invention also relates to a recombinant poxvirus vector from which at least one immune evasion gene has been deleted, which comprises a nucleic acid sequence encoding a 5T4 TAA and the use thereof in vaccinating against and in treating tumours.09-16-2010
20100233125CHIMERIC ADENOVIRUS, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL USING THE SAME - The invention relates to novel chimeric adenoviruses comprising the type 5-modified chimeric adenoviruses, in which the fiber knob domain in the adenoviruses type 5 is replaced by the adenoviruses type 35 fiber knob domain and any exogenous transcriptional regulatory regions controlling expression of the E1A and E1B genes are introduced into the region from which adenoviruses type 5 E1A transcriptional regulatory region has been removed. The chimeric adenoviruses are cytotoxic or oncolytic chimeric adenoviruses and can be utilized as, for example, pharmaceutical agents having high cytotoxic activity against intractable tumors such as malignant mesothelioma.09-16-2010
20100233124BACILLUS BASED DELIVERY SYSTEM AND METHODS OF USE09-16-2010
20110262399PORPHOBILINOGEN DEAMINASE GENE THERAPY - The present invention relates to nucleotide sequences coding for human porphobilinogen deaminase that are optimised for higher expression in mammalian cells. The invention further relates to DNA constructs comprising such optimised synthetic coding sequences for use in gene therapy of conditions caused by a deficiency in porphobilinogen deaminase, such as acute intermittent porphyria. Accordingly, the present invention relates to a nucleic acid or a nucleic acid construct comprising a nucleotide sequence coding for a human porphobilinogen deaminase, wherein at least 320 of the codons coding for the human porphobilinogen deaminase are identical to the codons in SEQ ID NO: 1 or wherein at least 305 of the codons coding for the human porphobilinogen deaminase are identical to the codons in SEQ ID NO: 3.10-27-2011
20110268701STRESS-RESPONSIVE INDUCTION OF A THERAPEUTIC AGENT AND METHODS OF USE - This invention relates to compositions and methods for selective expression of a heterologous nucleic acid sequence in a targeted tissue, and more particularly to the glucose regulated protein 78 (grp78) stress-responsive promoter and its use in gene therapy and the production of transgenic animals.11-03-2011
20120321592Method for Using a Bacillus Subtilis Strain to Enhance Animal Health - The present invention relates to a method for enhancing the health of an animal comprising administering to the animal a composition comprising 12-20-2012
20120093776METHODS FOR TREATING DISEASES USING A BONE MORPHOGENETIC PROTEIN - Described herein are methods, uses, and pharmaceutical compositions for treating heart disease that include a bone morphogenetic protein (BMP). In addition, described herein are methods, uses, and compositions for preventing or slowing fibrosis in diseased or injured tissue, and/or for preventing or slowing cell death in diseased or injured tissue.04-19-2012
20110286970METHOD FOR TREATING PARKINSON'S DISEASE - The present invention relates to the use of a filamentous bacteriophage, which displays an antibody that specifically binds to a pro-inflammatory cytokine, either alone or in combination with a filamentous bacteriophage that does not display a mammalian cell internalization signal, to treat Parkinson's disease.11-24-2011
20120328571Method for Using a Bacillus Subtilis Strain for Prophylaxis and Treatment of Gastro-Intestinal Conditions - The present invention relates to a method for enhancing the health of a human comprising administering to the human an effective amount of a composition comprising 12-27-2012
20100215619HLA PEPTIDE THERAPY - The invention provides polypeptides derived from a major histocompatibility complex (MHC) class I human leukocyte antigen (HLA), such as HLA-A2, and derivatives or analogues thereof. The polypeptides, derivatives and analogues can be used to treat or prevent allosensitisation, such as the treatment or prevention of allograft rejection.08-26-2010
20120100107IN VIVO TRANSFER METHODS FOR WOUND HEALING - The present invention relates to an in vivo method for specific targeting and transfer of DNA into mammalian repair cells. The transferred DNA may include any DNA encoding a therapeutic protein of interest. The invention is based on the discovery that mammalian repair cells proliferate and migrate into a wound site where they actively take up and express DNA. The invention further relates to pharmaceutical compositions that may be used in the practice of the invention to transfer the DNA of interest. Such compositions include any suitable matrix in combination with the DNA of interest.04-26-2012
20090047253Probiotic system for aquaculture - Probiotic bacterial strains are provided which inhibit or prevent growth or pathogenic bacteria in marine organisms. Also provided are methods of culturing marine organisms using the probiotic bacteria.02-19-2009
20100172871Muller Cell Specific Gene Therapy - The present invention provides methods and compositions for the treatment of disease of the eye, such as retinitis pigmentosa (RP) and glaucoma, by delivery of a transgene encoding a therapeutic polypeptide, such as glial cell-derived neurotrophic factor (GDNF), specifically to Müller glial cells using a gene delivery vector. In one embodiment, the gene delivery vector is a pseudotyped retroviral vector, particularly a lentiviral vector.07-08-2010
20130011367Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis - Isolated polynucleotide sequences exhibiting endothelial cell specific promoter activity, novel cis regulatory elements and methods of use thereof enabling treatment of diseases characterized by aberrant neovascularization or cell growth are disclosed.01-10-2013
20110158948Treatment Using Herpes Simplex Virus - Herpes Simplex Viruses are disclosed having single-chain antibodies (scFv) embedded in the viral envelope via fusion with glycoprotein D and with glycoprotein H and L.06-30-2011
20110158947SULFONYLUREA RECEPTOR AND MEANS FOR TREATING ISCHAEMIA - We disclose agents useful in the treatment of diseases or conditions that would benefit from improved muscle function and including pharmaceutical compositions and diagnostic tests for determining the predisposition of a subject, in particular a male subject, to cardiovascular disease.06-30-2011
20110158946Methods and Compositions for control of disease in aquaculture - The invention discloses paratransgenesis methods for prevention, amelioration and/or treatment of a disease or disorder in an aquatic animal. The method comprises providing a genetically modified micro algae that expresses a recombinant molecule that specifically targets one or more key epitopes of a pathogen that infects the aquatic animal and ii) feeding the aquatic animal directly or indirectly with the genetically modified unicellular algae.06-30-2011
20110158945MYXOMA VIRUS MUTANTS FOR CANCER TREATMENT - Myxoma viruses that are deficient in the activity of a Myxoma virus protein selected from the group consisting of M11L, M063, M 136, M-T4 and M-T7 are useful for treating cancer.06-30-2011
20130022574Avirulent Salmonella Gallinarum Variants and Pharmaceutical Composition Using the Same - The present invention relates to avirulent 01-24-2013
20130171107LONG LASTING DRUG FORMULATIONS - The present invention is directed to long-lasting therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes a therapeutic polypeptide, such as erythropoietin or interferon alpha.07-04-2013
20080247996Methods of treating neoplasia with combination target cell-specific adenovirus, chemotherapy and radiation - The invention provides methods of treating neoplasia using combinations of target cell-specific replication competent adenoviral vectors and chemotherapy, radiation therapy or combinations thereof. The adenoviral vectors are target cell-specific for the particular type of neoplasia for which treatment is necessary and the combination with the chemotherapy and/or radiation leads to synergistic treatment over existing adenoviral therapy or traditional chemotherapy and radiation therapy.10-09-2008
20080247995Wound and cutaneous injury healing with a nucleic acid encoding a proteoglycan polypeptide - The present disclosure provides nucleic acid constructs encoding one or more polypeptides containing at least one glycosaminoglycan chain, such as, but not limited to, a proteoglycan polypeptide, and methods for delivering to the site of a wound or cutaneous injury at least one nucleic acid construct encoding one or more such polypeptides, such that the expressed polypeptide is glycated by glycosaminoglycan chains through the normal physiological processes of the subject at the site of administration to produce a functional proteoglycan polypeptide for the healing of the wound or other cutaneous injury. The delivered nucleic acid construct is transcribed, translated and post-translationally modified by the addition of glycosaminoglycan chains (referred herein as “decoration” or “glycation”) to produce a decorated polypeptide. The decorated polypeptide is then secreted from the cell in which it was produced to provide treatment of wounds and/or cutaneous injury in the subject and/or prevention of cutaneous injury in a subject.10-09-2008
20080226602REOVIRUSES HAVING MODIFIED SEQUENCES - The invention provides for modified reovirus nucleic acid sequences and modified reovirus polypeptide sequences as well as reoviruses containing such modified nucleic acid or polypeptide sequences. The invention also provides for pharmaceutical compositions that include reoviruses having a modified sequence as well as methods of making and using such reoviruses.09-18-2008
20080226601Herpes Virus-Based Compositions and Methods of Use in the Prenatal and Perinatal Periods - Disclosed are compositions and methods for reducing the severity of a birth defect in a mammal by exposing the mammal (e.g., in utero) to a herpes virus amplicon particle comprising a cis element-flanked transgene and a sequence encoding a transposase. Upon expression, the transposase inserts the transgene into the genome of a cell (e.g., a neuron) within the mammal and the transgene expresses a polypeptide or RNA that compensates for a protein or gene defect that is causally associated with the birth defect.09-18-2008
20080226600Adeno-associated viruses and uses thereof - The invention provides an isolated and purified DNA molecule comprising at least one DNA segment, a biologically active subunit or variant thereof, of a circular intermediate of adeno-associated virus, which DNA segment confers increased episomal stability, persistence or abundance of the isolated DNA molecule in a host cell. The invention also provides a composition comprising at least two adeno-associated virus vectors.09-18-2008
20080226599Methods of treatment involving p21/CIP1 - The onset ratios and pathological conditions of collagen-induced arthritis and adjuvant arthritis in model mice and rats, respectively, were successfully ameliorated by topically expressing the cyclin-dependent kinase inhibitors p1609-18-2008
20080226598Compositions and methods for generating an immune response utilizing alphavirus-based vector systems - Methods are provided for generating immune responses utilizing alphavirus-based vector systems.09-18-2008
20130171106USE OF A COMBINATION OF MYXOMA VIRUS AND RAPAMYCIN FOR THERAPEUTIC TREATMENT - The present invention relates to therapeutic use of a combination of Myxoma virus, including in combination with rapamycin. Treatment with rapamycin enhances the ability of Myxoma virus to selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon. The combination of rapamycin and Myxoma virus can be used to treat diseases characterized by the presence of such cells, including cancer. The invention also relates to therapeutic use of Myxoma virus that does not express functional M135R.07-04-2013
20080247994DNA vaccine - The present invention relates to a DNA vaccine consisting of a vector expressing a part or the whole of a polypeptide regulating production of an inflammatory cytokine, a pharmaceutical composition comprising the DNA vaccine, and a method of preventing or treating an inflammatory disease by using the pharmaceutical composition.10-09-2008
20110274660PHARMACEUTICAL COMPOSITION TO PROTECT AN ANIMAL AGAINST A DISORDER ARISING FROM AN INFECTION WITH A BACTERIUM THAT BELONGS TO THE GROUP OF NOCARDIOFORM ACTINOMYCETES - The invention pertains to a pharmaceutical composition to protect an animal against a disorder arising from an infection with a bacterium that belongs to the group of nocardioform actinomycetes having the ability to survive within macrophages of the animal, comprising live bacteria of a nocardioform actinomycetes species, the live bacteria being attenuated by inactivation of a gene that encodes a protein involved in methylhexahydroindanedione propionate degradation, and a pharmaceutically acceptable carrier for these live bacteria.11-10-2011
20110274659Biological control agent for plants - A biological control agent for plants and a method of inoculating the plants with the biological control agent in order protect against plant disease are provided. The treatment method consists of inoculating the plant with a strain of cucumber mosaic virus (CMV), referred to as the KU1 strain, having an associated viral satellite RNA of SEQ ID NO: 1. Particularly, the KU1 strain may be used to protect plants against a particular viral strain of CMV, referred to as the KU2 strain, characterized by the associated viral satellite RNA of SEQ ID NO: 2, which causes tomato necrosis. Additionally, the KU1 strain may be used to protect against potato spindle tuber viroid (PSTV), which causes tomato stunting, fusarium wilt disease in the tomato (caused by 11-10-2011
20130095071METHOD OF TREATING OR PREVENTING HEARING LOSS - Disclosed herein is a method of delivering a mutated tyrosine adeno-associated viral vector or a pharmaceutically active agent to an inner ear. The method comprises contacting the round window membrane with the vector or the pharmaceutically active agent, in which the permeability of the round window membrane having been enhanced to allow transport of the vector or the pharmaceutically active agent across it so as to deliver the vector or the pharmaceutically active agent to the inner ear. Also disclosed are methods to prevent or treat hearing loss and impaired balance in human subjects using the delivery method.04-18-2013
20130095072THERAPEUTIC AGENT FOR ISCHEMIC DISEASES04-18-2013
20130101558AAV-BASED TREATMENT OF CHOLESTEROL-RELATED DISORDERS - The invention in some aspects relates to methods and compositions for assessing the effectiveness of miRNA inhibitors. In other aspects of the invention, methods and compositions for treating cholesterol related disorders are provided. In one aspect of the invention, miRNA inhibitors against miR-122 and rAAV-based compositions comprising the same are provided.04-25-2013
20130129683Modified Rodent Parvovirus Capable of Propagating and Spreading Through Human Gliomas - Described are (a) parvovirus variants capable of propagating and spreading through human tumor cells which is obtainable by serially passaging a rodent parvovirus as starting strain in semi-permissive human tumor cells, and (b) parvovirus variants capable of propagating and spreading through human tumor cells characterized by particular amino acid deletions and/or substitutions, e.g. a deletion of several amino acids in the C-terminus of NS1/middle exon of NS2. A pharmaceutical composition containing such parvoviruses as well as their use for the treatment of cancer, preferably a glioblastoma, is also described.05-23-2013
20130129682HAEMOPHILUS PARASUIS POLYPEPTIDES AND METHODS OF USE - The present invention provides isolated polypeptides having oligopeptide permease activity and an amino acid sequence that has at least 80% identity with a 05-23-2013
20130142759BIOCONTROL OF NEMATODES - A method for controlling nematodes in or on a plant, a plant part, and/or a locus for plant growth is provided, the method comprising applying to a plant, plant part, or locus for plant growth in need of protection from said nematodes an effective amount of 06-06-2013
20130101557Recombinant Adenovirus Having Anti-Angiogenesis Activity - The present disclosure relates to a recombinant adenovirus with improved angiogenesis inhibition activity and a pharmaceutical composition for inhibiting angiogenesis. The recombinant adenovirus includes: (a) an inverted terminal repeat (ITR) nucleotide sequence of an adenovirus; and (b) a nucleotide sequence coding for a chimeric decoy receptor containing (i) an extracellular domain of vascular endothelial growth factor receptor 1 (VEGFR-1) and (ii) an extracellular domain of vascular endothelial growth factor receptor 2 (VEGFR-2). The recombinant adenovirus according the present disclosure which expresses the chimeric decoy receptor inhibits angiogenesis very effectively and can be used for gene therapy for various angiogenesis-related diseases. Particularly, the recombinant adenovirus of the present disclosure has superior oncolytic activity.04-25-2013
20080206197Metabolically activated recombinant viral vectors and methods for their preparation and use - Recombinant viral vectors, especially parvovirus vectors such as adeno-associated virus (AAV) vectors, capable of enhanced expression of heterologous sequences, and methods for their construction and use, are provided. The vectors have a structure, or are capable of rapidly adopting a structure, which involves intrastrand base pairing of at least one region in a heterologous sequence.08-28-2008
20090162321METHODS FOR PACKAGING PROPAGATION-DEFECTIVE VESICULAR STOMATITIS VIRUS VECTORS USING A STABLE CELL LINE THAT EXPRESSES G PROTEIN - A method of producing propagation-defective Vesicular Stomatitis Virus (VSV) is provided. The method involves providing a cell that includes an optimized VSV G gene, wherein expression of VSV G protein from the optimized VSV G gene is inducible; and inducing the cell to express VSV G protein from the optimized VSV G gene. The method also involves infecting the induced cell with an attenuated VSV; growing the infected cells in culture; and recovering attenuated VSV from the culture.06-25-2009
20080199435IL-8 Like Protein - This present invention relates to a novel protein, termed INSP085, herein identified as an IL-8 like protein and to the use of this protein and nucleic acid sequence from the encoding genes in the diagnosis, prevention and treatment of disease.08-21-2008
20080199434COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR CONDITIONS - The present invention provides methods and compositions for treating a cardiovascular condition. In particular, provided is a method comprising administering to a subject an agent that increases the level and/or activity of angiotensin II type 2 receptors. Also provided is a method for evaluating the risk of having or developing a cardiovascular condition08-21-2008
20080199433Complementing cell lines - A packaging cell line that complements recombinant adenoviruses based on serotypes from subgroup B, preferably adenovirus type 35. The cell line is preferably derived from primary, diploid human cells that are transformed by adenovirus E1 sequences either operatively linked on one DNA molecule or located on two separate DNA molecules, the sequences being operatively linked to regulatory sequences enabling transcription and translation of encoded proteins. Also disclosed is a cell line derived from PER.C6 that expresses functional Ad35 E1B sequences. The Ad35-E1B sequences are driven by the E1B promoter or a heterologous promoter and terminated by a heterologous poly-adenylation signal. The cell lines are useful for producing recombinant adenoviruses designed for gene therapy and vaccination. The cell lines can also be used for producing human recombinant therapeutic proteins such as human growth factors and human antibodies. Also, the cell lines are useful for producing human viruses other than adenovirus such as influenza virus, herpes simplex virus, rotavirus, and measles virus.08-21-2008
20080199432ROLE FOR SRY IN PARKINSON'S DISEASE - The present invention relates to a method for treating or preventing Parkinson's disease in a patient, the method comprising administering to the patient a therapeutically effective population of neuronal cells transformed with a nucleic acid molecule encoding SRY, wherein the transformed cells express SRY.08-21-2008
20130142760ATHEROSCLEROSIS INHIBITION VIA MODULATION OF MONOCYTE-MACROPHAGE PHENOTYPE USING APO A-I MILANO GENE TRANSFER - A method of changing the phenotype of monocytes and macrophages from a pro inflammatory MI phenotype to an anti-inflammatory M2 phenotype is disclosed. The method can comprises providing a composition comprising a recombinant adeno-associated virus (rAAV) vector comprising an exogenous gene encoding ApoA-1 Milano or a fragment thereof, and administering the composition to mammal in need thereof to change the phenotype of monocytes or macrophages from a pro inflammatory M1 phenotype to an anti inflammatory M2 phenotype. By changing the phenotype of monocytes or macrophages from a pro-inflammatory M1 phenotype to anti-inflammatory M2 phenotype, atherosclerosis can be treated. A method of monitoring macrophage phenotypic switching and a method of assessing the efficacy of the treatment of atherosclerosis are also described.06-06-2013
20110236353ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR - Sequences of novel adeno-associated virus capsids and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles. AAV-mediated delivery of therapeutic and immunogenic genes using the vectors of the invention is also provided.09-29-2011
20120276053ONCOLYTIC VACCINIA VIRUS CANCER THERAPY - Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include administering the vaccinia virus at increased viral concentrations. Further aspects of the invention include methods for inducing oncolysis or collapse of tumor vasculature in a subject having a tumor comprising administering to a subject at least 1×1011-01-2012
20120276052TRANSGENE DELIVERING RETROVIRUS TARGETING COLLAGEN EXPOSED AT SITE OF TISSUE INJURY - A viral or non-viral vector particle having a modified viral surface protein wherein the viral surface protein is modified to include a targeting polypeptide including a binding region which binds to an extracellular matrix component. Such vector particles are useful in delivering genes encoding therapeutic agents to cells located at the site of an exposed extracellular matrix component.11-01-2012
20100291036COMPOSITIONS AND METHODS FOR MODULATING VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) EXPRESSION - The present invention relates to compounds and methods for inhibiting the expression of vascular endothelial growth factor-C (VEGF-C) in a target cell. Particularly, the present invention relates to antisense polynucleotides complementary to a lens epithelium-derived growth factor (LEDGF/p75) mRNA and uses thereof for inhibiting tumor progression and tumor metastasis. The present invention further relates to uses of LEDGF/p75 polypeptide or a nucleic acid encoding same for treating endothelial cell related conditions, particularly inflammation and edema.11-18-2010
20100316611Self-containing lactococcus strain - The invention relates to a recombinant 12-16-2010
20100316610MUTANT HAVING URACIL PHOSPHORIBOSYL TRANSFERASE ACTIVITY - The invention concerns a polypeptide having a uracil phosphoribosyl transferase (UPRTase) by mutation of one or several residues of the UPRTase. The invention also concerns a nucleotide sequence coding for the UPRTase mutant, a vector for expressing the latter, a viral particle, a host cell, and a composition containing them. The invention further concerns their therapeutic use and a treatment method using them. The invention is particularly useful in the context of therapy by suicide genes, in particular, for treating proliferative and infectious diseases.12-16-2010
20100316609Conditionally Replicating Viruses for Cancer Therapy - Described herein are viral vectors comprising a nucleic acid encoding a viral DNA polymerase wherein the encoded viral DNA polymerase comprises at least one amino acid modification. Also provided are methods of making and using the viral vectors.12-16-2010
20130156736COMPLEMENTING CELL LINES - A packaging cell line that complements recombinant adenoviruses based on serotypes from subgroup B, preferably adenovirus type 35. The cell line is preferably derived from primary, diploid human cells that are transformed by adenovirus E1 sequences either operatively linked on one DNA molecule or located on two separate DNA molecules, the sequences being operatively linked to regulatory sequences enabling transcription and translation of encoded proteins. Also disclosed is a cell line derived from PER.C6 that expresses functional Ad35 E1B sequences. The Ad35-E1B sequences are driven by the E1B promoter or a heterologous promoter and terminated by a heterologous poly-adenylation signal. The cell lines are useful for producing recombinant adenoviruses designed for gene therapy and vaccination. The cell lines can also be used for producing human recombinant therapeutic proteins such as human growth factors and human antibodies. Also, the cell lines are useful for producing human viruses other than adenovirus such as influenza virus, herpes simplex virus, rotavirus, and measles virus.06-20-2013
20130156737Secretion System and Methods for its Use - The present invention provides reagents and methods for inhibiting bacterial infection and abnormal cell growth, as well as for selection cloning of nucleic acid inserts.06-20-2013
20120282225METHOD AND COMPOSITION FOR CREATING CONDITIONAL LETHALITY FOR VIRUS MUTANTS AND FOR ELIMINATING THE VIABILITY OF AN EUKARYOTIC CELL - Viral vectors are potential tools for eliminating the viability of eukaryotic cells in anti-cancer therapies since they can efficiently destroy the cancer cells and trigger an immune response against tumours. Typically viruses are not specific to cancer cells and all methods known in art aiming to the construction of cancer-specific viruses suffer from serious problems. The present invention presents a universal method to overcome these problems and is usable for any DNA virus replicating in nucleus or for any layered vector of RNA viruses. In this method the viral gene expression and/or replication will be blocked by the introduction of one or more aberrantly spliced introns into crucial gene expression units of the virus or vector. Lethal effect of these mutations is reverted in a controlled manner by the delivery of splice-switch oligonucleotide (s) correcting the introduced defects and restoring the biological functionality of the virus or vector, including cytolytic properties.11-08-2012
20110311489OPTICALLY-BASED STIMULATION OF TARGET CELLS AND MODIFICATIONS THERETO - Stimulation of target cells using light, e.g., in vivo or in vitro, is implemented using a variety of methods and devices. One example involves a vector for delivering a light-activated molecule comprising a nucleic acid sequence that codes for light-activated molecule. The light-activated molecule includes a modification to a location near the all-trans retinal Schiff base, e.g., to extends the duration time of the open state. Other aspects and embodiments are directed to systems, methods, kits, compositions of matter and molecules for ion channels or pumps or for controlling currents in a cell (e.g., in in vivo and in vitro environments).12-22-2011
20110311488MODIFIED BACTERIAL CELL - We describe modified bacterial cells that are defective in gene expression and their use in the treatment of bacterial infections of animals and plants and the inhibition of bacterial biofilm formation.12-22-2011
20110311487DELIVERY OF THERAPEUTIC AGENTS TO THE BONE - This invention relates to compositions and methods of delivering therapeutic agents to bone. More specifically, the invention relates to endowing a large molecule vectors i.e., adeno virus, retrovirus, liposomes, micelles, natural and synthetic polymers, or combinations thereof, with the ability to target bone tissue in vivo and with improved stability in the blood, by attaching multiple copies of acid amino acid peptides. One preferred embodiment of the invention relates to endowing an adeno-associated virus (AAV) vector with the ability to target bone-tissue in vivo and improve its stability, by the addition of multiple acidic amino acid peptides attached to the capsid of the viral vector.12-22-2011
20130189227Biocontrol of Nematodes - The present invention provides a method for using a 07-25-2013
20120014921TREATMENT OF STROKE AND OTHER ACUTE NEURAL DEGENERATIVE DISORDERS VIA INTRANASAL ADMINISTRATION OF UMBILICAL CORD-DERIVED CELLS - This invention relates to methods of treating stroke by intranasal administration of umbilical cord tissue-derived cells, which are isolated from mammalian umbilical cord tissue substantially free of blood or expanded in culture from a cell isolated from mammalian umbilical cord tissue substantially free of blood, are capable of self-renewal and expansion in culture, and do not produce CD117 and/or telomerase. The methods of the invention regenerate, repair and improve neural tissue and improve behavior and neurological function in stroke patients.01-19-2012
20120020924NOVEL RECOMBINANT ADENOVIRUS VECTOR HAVING A REDUCED SIDE EFFECT - The present invention provides a novel adenovirus vector for which inflammation during the in vivo administration thereof is alleviated by inhibiting the induction of expression of an adenovirus gene by a foreign promoter inserted into the adenovirus genome, and a method for producing the vector, a cell line for use in the production of the recombinant adenovirus vector, or a gene therapy method using the recombinant adenovirus vector.01-26-2012
20120027727TARGETED NANOPARTICLES FOR CANCER AND OTHER DISORDERS - Targeted gene therapeutic systems are provided for the treatment of cancer, including viral particles. The viral particles are engineered to specifically deliver therapeutic or diagnostic agents to a disease site, such as cancer metastatic sites. Localized dosing regimens are provided to treat diseases such as cancer.02-02-2012
20120027726Methods for Distributing High Levels of Therapeutic Agent Throughout the Cortex to Treat Neurological Disorders - The invention provides methods for treating neurological disorders, which involve administering therapeutic agents to the thalamus by convection enhanced delivery.02-02-2012
20120027725SAFE LENTIVIRAL VECTORS FOR TARGETED DELIVERY OF MULTIPLE THERAPEUTIC MOLECULES TO TREAT LIVER CANCER - The present application discloses a lentiviral transfer system for treating liver cancer which includes: (i) a self-inactivating transfer vector comprising: multiple gene units, wherein each gene unit includes a heterologous nucleic acid sequence operably linked to a regulatory nucleic acid sequence; and (ii) a helper construct which lacks a 5′ LTR, wherein the 5′ LTR has been replaced with a heterologous promoter, in which the helper construct further comprises: a lentiviral env nucleic acid sequence containing a deletion, wherein the deleted env nucleic acid sequence does not produce functional env protein; and a packaging signal contains a deletion, wherein the deleted packaging signal is nonfunctional.02-02-2012
20130195802Cellular Constituents From Bacteroides, Compositions Thereof, and Therapeutic Methods Employing Bacteroides or Cellular Constituents Thereof - A cellular constituent is lysed from, produced by and/or isolated from one or more bacteria from the genus 08-01-2013
20130195801CNS TARGETING AAV VECTORS AND METHODS OF USE THEREOF - The invention in some aspects relates to recombinant adeno-associated viruses useful for targeting transgenes to CNS tissue, and compositions comprising the same, and methods of use thereof. In some aspects, the invention provides methods and compositions for treating CNS-related disorders.08-01-2013
20130195800Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof - This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing vectors for one or more immunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. These vector may be provided to treat a variety of disorders, e.g., neoplastic disorders, through direct injection or through in vitro engineered cells, such as dendritic cells.08-01-2013
20130202559Use of Microvesicles in the Treatment of Medical Conditions - This invention relates generally to populations of microvesicles containing or otherwise associated with viral particles, methods of producing these purified populations, and methods of using these purified populations in a variety of diagnostic, therapeutic and/or prophylactic indications.08-08-2013
20130202560PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION AND TREATMENT CONTAINING THE C12ORF59 GENE OR PROTEIN AS AN ACTIVE INGREDIENT - As explained hereinbefore, the C12orf59 gene of the present invention suppresses cancer cell invasion and inhibits cancer cell survivability, and the over-expression of C12orf59 protein or a fragment thereof inhibits cancer cell invasion, so that C12orf59 gene or a fragment thereof not only can be effectively used for the pharmaceutical composition for preventing and treating cancer but also can be used as a clinical marker for screening a cancer treatment agent candidate, for diagnosing various cancers or for predicting pathological stage. In addition, the C12orf59 gene or a fragment thereof of the present invention can be used for the method for preventing and treating cancer and for the preparation of a pharmaceutical composition for preventing and treating cancer.08-08-2013
20130202558RECOMBINANT REPLICATION COMPETENT ONCOLYTIC VIRUSES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER - Improved NCD variants exhibiting enhanced bioavailability and stability for the treatment of cancer are provided.08-08-2013
20130202557ORAL DELIVERY OF NUCLEIC ACID-BASED GENE INTERFERING AGENTS BY SALMONELLA - The present invention provides vectors, including a novel attenuated strain of 08-08-2013
20100040578Malignant Tumor Cell Suppressor Protein, Malignant Tumor Cell Suppressor Gene, Maligant Tumor Cell Suppressive Viral Vector, and Kit Using the Same - A malignant tumor cell suppressor protein (a) or (b): 02-18-2010
20120064038EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND METHODS OF USE IN ADENOVIRAL-ASSOCIATED VIRUS TYPE 6 (AAV6) TRANSDUCTION - Comparative gene analysis (CGA) was combined with pathway visualization software to identify a positive correlation between AAV6 transduction and epidermal growth factor receptor (EGFR) expression. It was found that EGFR is necessary for vector internalization and functions as a co-receptor for AAV6. The identification and characterization of AAV6's requirement of EGFR expression for high transduction activity has allowed construction of recombinant AAV6 vectors which are capable of targeting and killing specific types of head and neck tumors that because of this high EGFR activity, were until now, refractory to current therapies.03-15-2012
20120093775METHODS AND COMPOSITIONS FOR THE TREATMENT OF CIRRHOSIS AND LIVER FIBROSIS - The invention provides a method for the treatment of cirrhosis and liver fibrosis by the use or viral vectors containing the gene encoding IGF-I. The invention discloses both parvoviral vectors and SV40-based vectors as well uses thereof for the treatment of cirrhosis and gene therapy and methods for the preparation of said viral vectors.04-19-2012
20120093778SIMIAN ADENOVIRUS NUCLEIC ACID AND AMINO ACID SEQUENCES, VECTORS CONTAINING SAME, AND METHODS OF USE - A recombinant vector comprises simian adenovirus sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.04-19-2012
20120093777COMPOSITIONS COMPRISING VIRUSES AND METHODS FOR CONCENTRATING VIRUS PREPARATIONS - A composition is disclosed comprising virus in a formulation comprising a polyhydroxy hydrocarbon buffered to maintain a pH in a range from about 7 to about 8.5 at a temperature in the range from about 2° C. to 27° C. Methods for concentrating and purifying virus preparations are also disclosed.04-19-2012
20120093774AUXOTROPHIC RECOMBINANT BCG STRAIN PASTEUR AND USE THEREOF IN THE CONTROL OF HUMAN INFECTIONS CAUSED BY PARASITES - The present invention relates to a vaccinal strain of recombinant BCG 04-19-2012
20120093773Compositions for Bacterial Mediated Gene Silencing and Methods of Using Same - Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating cancer of cell proliferative disorders. The bacterium includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells.04-19-2012
20120093772VECTORS FOR DELIVERY OF LIGHT SENSITIVE PROTEINS AND METHODS OF USE - Provided herein are compositions and methods for gene and etiology-nonspecific and circuit-specific treatment of diseases, utilizing vectors for delivery of light-sensitive proteins to diseased and normal cells and tissues of interest.04-19-2012
20130209407LIVE MICROBIAL MICROBICIDES - The present invention relates, e.g., to a commensal bacterium which can colonize the genitourinary and/or gastrointestinal mucosa, and which, under suitable conditions, secretes a heterologous antimicrobial polypeptide, wherein the secreted antimicrobial polypeptide is effective to inhibit infectivity by, or a pathogenic activity of, a pathogen. In a most preferred embodiment, the antimicrobial polypeptide inhibits HIV infection (e.g., fusion) and/or pathogenesis. Also described are preventive or therapeutic compositions comprising the commensal bacteria, and methods to inhibit infectivity and/or pathogenesis, using the bacteria.08-15-2013
20130209408BACTERIOPHAGE-CONTAINING THERAPEUTIC AGENTS - The present invention relates in its broadest aspect to combined phage/antibiotic therapy. More particularly, it relates to use of (i) one or more bacteriophages and (ii) one or more antibiotics in the manufacture of a combined product for simultaneous, separate or sequential administration of (i) and (ii) to treat a bacterial infection characterized by biofilm formation, for example an infection comprising or consisting of 08-15-2013
20130209409CHIMERIC ADENOVIRUSES FOR USE IN CANCER TREATMENT - The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.08-15-2013
20130209410EXPRESSION VECTOR FOR CHOLESTEROL 24 -HYDROLASE IN THERAPY OF HUNTINGTON'S DISEASE - The present invention relates to a vector for use in the treatment of Huntington's disease, which vector comprises a cholesterol 24-hydroxylase encoding nucleic acid.08-15-2013
20130209406RECOMBINANT RNA VIRUSES AND USES THEREOF - Described herein are modified RNA virus gene segments and nucleic acids encoding modified RNA virus gene segments. Also described herein are recombinant RNA viruses comprising modified RNA virus gene segments and the use of such recombinant RNA viruses for the prevention and treatment of disease.08-15-2013

Patent applications in class Genetically modified micro-organism, cell, or virus (e.g., transformed, fused, hybrid, etc.)

Patent applications in all subclasses Genetically modified micro-organism, cell, or virus (e.g., transformed, fused, hybrid, etc.)